US10106555B2 - Max binders as MYC modulators and uses thereof - Google Patents

Max binders as MYC modulators and uses thereof Download PDF

Info

Publication number
US10106555B2
US10106555B2 US15/435,003 US201715435003A US10106555B2 US 10106555 B2 US10106555 B2 US 10106555B2 US 201715435003 A US201715435003 A US 201715435003A US 10106555 B2 US10106555 B2 US 10106555B2
Authority
US
United States
Prior art keywords
substituted
unsubstituted
alkyl
certain embodiments
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US15/435,003
Other languages
English (en)
Other versions
US20170233405A1 (en
Inventor
Angela N. Koehler
Eric Stefan
Francisco Caballero
Dylan Vijith Neel
Nicholas B. Struntz
Helen L. Evans
Andrew Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Priority to US15/435,003 priority Critical patent/US10106555B2/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Assigned to MASSACHUSETTS INSTITUTE OF TECHNOLOGY reassignment MASSACHUSETTS INSTITUTE OF TECHNOLOGY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STEFAN, Eric, KOEHLER, ANGELA N., EVANS, Helen L., NEEL, Dylan Vijith, CABALLERO, Francisco, CHEN, ANDREW, STRUNTZ, Nicholas B.
Assigned to MASSACHUSETTS INSTITUTE OF TECHNOLOGY reassignment MASSACHUSETTS INSTITUTE OF TECHNOLOGY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STEFAN, Eric, KOEHLER, ANGELA N., EVANS, Helen L., NEEL, Dylan Vijith, CABALLERO, Francisco, CHEN, ANDREW, STRUNTZ, Nicholas B.
Publication of US20170233405A1 publication Critical patent/US20170233405A1/en
Priority to US16/167,238 priority patent/US10865213B2/en
Application granted granted Critical
Publication of US10106555B2 publication Critical patent/US10106555B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Definitions

  • MAX MYC associated factor X
  • bHLHZ basic helix-loop-helix leucine zipper
  • the homodimers and heterodimers compete for a common DNA target site (the E box), and rearrangement among these dimeric forms provides a complex system of transcriptional regulation.
  • Activation of c-MYC is one of the most common oncogenic events in human malignancies [1, 2].
  • the Myc family of transcription factors (MYC, MYCL, and MYCN) regulates a diverse set of biological processes including DNA replication, gene transcription, and protein translation.
  • Myc apoptosis
  • metabolism apoptosis
  • differentiation apoptosis
  • angiogenesis angiogenesis
  • Myc activation can occur through several mechanisms such as point mutation, somatic gene amplification, chromosomal translocation, overexpression, enhanced translation, and increased protein stability [2].
  • point mutation point mutation
  • somatic gene amplification chromosomal translocation
  • overexpression enhanced translation
  • protein stability increased protein stability
  • Myc and MAX dimerize in order to bind DNA and initiate transcription Myc can be indirectly targeted by using compounds that bind MAX. If these compounds reduce Myc transcriptional activity in human cancers, they may also cause tumor regression. Thus, MAX binding compounds have potential in cancer treatment and may provide an indirect way of targeting of Myc in treating cancer and other proliferative diseases.
  • described herein are compounds of Formula (I′), Formula (I), Formula (II), Formula (II-A), Formula (III), Formula (IV), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof.
  • the compounds described herein may be binders of MAX and/or modulators (e.g., inhibitors) of Myc (e.g., c-Myc, L-Myc, N-Myc), Mad, or Mxi1.
  • the compounds may be useful in modulating (e.g., inhibiting) the activity of Myc, Mad, or Mxi1 in a subject in need thereof, treating diseases associated with Myc (e.g., diseases associated with aberrant activity (e.g., increased activity) of Myc) in a subject in need thereof, treating diseases in a subject in need thereof (e.g., proliferative diseases), preventing diseases associated with Myc (e.g., diseases associated with aberrant activity (e.g., increased activity) of Myc) in a subject in need thereof, preventing diseases in a subject in need thereof (e.g., proliferative diseases), and/or as research tools (e.g., for studying Myc and Myc-associated transcription (e.g., studying the activity of Myc) in a subject, biological sample, tissue, or cell).
  • a compound described herein e.g., a compound of Formula (I′), Formula (I), Formula (II), Formula (I
  • the present invention provides compounds of Formula (I′):
  • R 1 , R 2 , R 4 , R A1 , R A2 , a, and b are as defined herein.
  • R 1 , R 2 , R 3 , R A , R A1 , a, b, and x are as defined herein.
  • Exemplary compounds of Formulae (I′) and (I) include, but are not limited to:
  • Exemplary compounds of Formulae (I′) and (I) include, but are not limited to:
  • R B1 , R B2 , R B3 , R B4 , R B5 , and j are as defined herein.
  • Exemplary compounds of Formula (II) include, but are not limited to:
  • R B1 , R B2 , R B3 , and R B4 are as defined herein.
  • Exemplary compounds of Formula (II-A) include, but are not limited to:
  • R D1 , R D2 , R D3 , R D4 , R D5 , y, and z are as defined herein.
  • Exemplary compounds of Formula (III) include, but are not limited to:
  • R E1 , R E2 , R E3 , R E4 , R E5 , g, and h are as defined herein.
  • Exemplary compounds of Formula (IV) include, but are not limited to:
  • compositions including a compound described herein, and optionally a pharmaceutically acceptable excipient.
  • a pharmaceutical composition described herein includes an effective amount (e.g., therapeutically effective amount or prophylactically effective amount) of a compound described herein.
  • compositions may be useful in modulating (e.g., inhibiting) the activity of Myc, Mad, or Mxi1 in a subject in need thereof, treating diseases associated with Myc (e.g., diseases associated with aberrant activity (e.g., increased activity) of Myc) in a subject in need thereof, treating diseases in a subject in need thereof (e.g., proliferative disease), preventing diseases associated with Myc (e.g., diseases associated with aberrant activity (e.g., increased activity) of Myc) in a subject in need thereof, preventing diseases in a subject in need thereof (e.g., proliferative disease), and/or as research tools (e.g., for studying Myc (e.g., studying the activity of Myc, studying transcription modulated by Myc) in a subject, biological sample, tissue, or cell).
  • diseases associated with Myc e.g., diseases associated with aberrant activity (e.g., increased activity) of Myc
  • preventing diseases in a subject in need thereof
  • the disease being treated and/or prevented by a compound described herein is a proliferative disease.
  • the disease is associated with aberrant activity (e.g., increased or decreased activity) of Myc.
  • the disease is associated with increased activity of Myc.
  • the disease is associated with increased stability of Myc.
  • the disease is cancer (e.g., lung cancer, brain cancer, or lymphoma).
  • kits described herein are useful in treating and/or preventing proliferative diseases (e.g., cancer (e.g., lung cancer, breast cancer, leukemia, lymphoma, melanoma, multiple myeloma, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject, biological sample, tissue, or cell.
  • proliferative diseases e.g., cancer (e.g., lung cancer, breast cancer, leukemia, lymphoma, melanoma, multiple myeloma, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject, biological sample, tissue, or cell.
  • kits including a container with a compound or pharmaceutical composition described herein.
  • kits may be useful in modulating (e.g., inhibiting) the activity of Myc, Mad, or Mxi1, treating and/or preventing diseases (e.g., proliferative diseases, diseases associated with Myc, aberrant activity (e.g., increased activity) of Myc) in a subject in need thereof, and useful as research tools (e.g., for studying Myc (e.g., studying the activity of Myc) in a subject, biological sample, tissue, or cell).
  • a kit described herein further includes instructions for using the compound or pharmaceutical composition included in the kit.
  • Another aspect of the present disclosure relates to methods of treating and/or preventing a disease in a subject in need thereof, the methods comprising administering to the subject in need thereof an effective amount of a compound or pharmaceutical composition described herein.
  • the present disclosure provides compounds and pharmaceutical compositions described herein for use in a method of the disclosure (e.g., for use treating and/or preventing a disease (e.g. proliferative disease)).
  • a disease e.g. proliferative disease
  • Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., enantiomers and/or diastereomers.
  • the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer.
  • Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses.
  • HPLC high pressure liquid chromatography
  • C 1-6 is intended to encompass, C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5 , C 3-4 , C 4-6 , C 4-5 , and C 5-6 .
  • aliphatic includes both saturated and unsaturated, straight chain (i.e., unbranched), branched, acyclic, cyclic, or polycyclic aliphatic hydrocarbons, which are optionally substituted with one or more functional groups.
  • “aliphatic” is intended herein to include, but is not limited to, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and cycloalkynyl moieties.
  • alkyl includes straight, branched and cyclic alkyl groups. An analogous convention applies to other generic terms such as “alkenyl”, “alkynyl”, and the like.
  • alkyl encompass both substituted and unsubstituted groups.
  • lower alkyl is used to indicate those alkyl groups (cyclic, acyclic, substituted, unsubstituted, branched or unbranched) having 1-6 carbon atoms.
  • the alkyl, alkenyl, and alkynyl groups employed in the disclosure contain 1-20 aliphatic carbon atoms. In certain other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the disclosure contain 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the disclosure contain 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the disclosure contain 1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the disclosure contain 1-4 carbon atoms.
  • Illustrative aliphatic groups thus include, but are not limited to, for example, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, —CH 2 -cyclopropyl, vinyl, allyl, n-butyl, sec-butyl, isobutyl, tert-butyl, cyclobutyl, —CH 2 -cyclobutyl, n-pentyl, sec-pentyl, isopentyl, tert-pentyl, cyclopentyl, —CH 2 -cyclopentyl, n-hexyl, sec-hexyl, cyclohexyl, —CH 2 -cyclohexyl moieties and the like, which again, may bear one or more substituents.
  • Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, and the like.
  • Representative alkynyl groups include, but are not limited to, ethynyl, 2-propynyl (propargyl), 1-propynyl, and the like.
  • alkyl refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 10 carbon atoms (“C 1-10 alkyl”). In some embodiments, an alkyl group has 1 to 9 carbon atoms (“C 1-9 alkyl”). In some embodiments, an alkyl group has 1 to 8 carbon atoms (“C 1-8 alkyl”). In some embodiments, an alkyl group has 1 to 7 carbon atoms (“C 1-7 alkyl”). In some embodiments, an alkyl group has 1 to 6 carbon atoms (“C 1-6 alkyl”). In some embodiments, an alkyl group has 1 to 5 carbon atoms (“C 1-5 alkyl”).
  • an alkyl group has 1 to 4 carbon atoms (“C 1-4 alkyl”). In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C 1-3 alkyl”). In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C 1-2 alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“C 1 alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C 2-6 alkyl”).
  • C 1-6 alkyl groups include methyl (C 1 ), ethyl (C 2 ), propyl (C 3 ) (e.g., n-propyl, isopropyl), butyl (C 4 ) (e.g., n-butyl, tert-butyl, sec-butyl, iso-butyl), pentyl (C 5 ) (e.g., n-pentyl, 3-pentanyl, amyl, neopentyl, 3-methyl-2-butanyl, tertiary amyl), and hexyl (C 6 ) (e.g., n-hexyl).
  • alkyl groups include n-heptyl (C 7 ), n-octyl (C 8 ), and the like. Unless otherwise specified, each instance of an alkyl group is independently unsubstituted (an “unsubstituted alkyl”) or substituted (a “substituted alkyl”) with one or more substituents (e.g., halogen, such as F).
  • substituents e.g., halogen, such as F
  • the alkyl group is an unsubstituted C 1-10 alkyl (such as unsubstituted C 1-6 alkyl, e.g., —CH 3 (Me), unsubstituted ethyl (Et), unsubstituted propyl (Pr, e.g., unsubstituted n-propyl (n-Pr), unsubstituted isopropyl (i-Pr)), unsubstituted butyl (Bu, e.g., unsubstituted n-butyl (n-Bu), unsubstituted tert-butyl (tert-Bu or t-Bu), unsubstituted sec-butyl (sec-Bu), unsubstituted isobutyl (i-Bu)).
  • the alkyl group is a substituted C 1-10 alkyl (such as substituted C 1-6 alkyl, e.g.,
  • Alkenyl refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon-carbon double bonds, and no triple bonds (“C 2-20 alkenyl”). In some embodiments, an alkenyl group has 2 to 10 carbon atoms (“C 2-10 alkenyl”). In some embodiments, an alkenyl group has 2 to 9 carbon atoms (“C 2-9 alkenyl”). In some embodiments, an alkenyl group has 2 to 8 carbon atoms (“C 2-8 alkenyl”). In some embodiments, an alkenyl group has 2 to 7 carbon atoms (“C 2-7 alkenyl”).
  • an alkenyl group has 2 to 6 carbon atoms (“C 2-6 alkenyl”). In some embodiments, an alkenyl group has 2 to 5 carbon atoms (“C 2-5 alkenyl”). In some embodiments, an alkenyl group has 2 to 4 carbon atoms (“C 2-4 alkenyl”). In some embodiments, an alkenyl group has 2 to 3 carbon atoms (“C 2-3 alkenyl”). In some embodiments, an alkenyl group has 2 carbon atoms (“C 2 alkenyl”). The one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl).
  • Examples of C 2-4 alkenyl groups include ethenyl (C 2 ), 1-propenyl (C 3 ), 2-propenyl (C 3 ), 1-butenyl (C 4 ), 2-butenyl (C 4 ), butadienyl (C 4 ), and the like.
  • Examples of C 2-6 alkenyl groups include the aforementioned C 2-4 alkenyl groups as well as pentenyl (C 5 ), pentadienyl (C 5 ), hexenyl (C 6 ), and the like. Additional examples of alkenyl include heptenyl (C 7 ), octenyl (C 8 ), octatrienyl (C 8 ), and the like.
  • each instance of an alkenyl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents.
  • the alkenyl group is unsubstituted C 2-10 alkenyl.
  • the alkenyl group is substituted C 2-10 alkenyl.
  • a C ⁇ C double bond for which the stereochemistry is not specified e.g., —CH ⁇ CHCH 3 or
  • Alkynyl refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon-carbon triple bonds, and optionally one or more double bonds (“C 2-20 alkynyl”).
  • an alkynyl group has 2 to 10 carbon atoms (“C 2-10 alkynyl”).
  • an alkynyl group has 2 to 9 carbon atoms (“C 2-9 alkynyl”).
  • an alkynyl group has 2 to 8 carbon atoms (“C 2-8 alkynyl”).
  • an alkynyl group has 2 to 7 carbon atoms (“C 2-7 alkynyl”).
  • an alkynyl group has 2 to 6 carbon atoms (“C 2-6 alkynyl”). In some embodiments, an alkynyl group has 2 to 5 carbon atoms (“C 2-5 alkynyl”). In some embodiments, an alkynyl group has 2 to 4 carbon atoms (“C 2-4 alkynyl”). In some embodiments, an alkynyl group has 2 to 3 carbon atoms (“C 2-3 alkynyl”). In some embodiments, an alkynyl group has 2 carbon atoms (“C 2 alkynyl”). The one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl).
  • Examples of C 2-4 alkynyl groups include, without limitation, ethynyl (C 2 ), 1-propynyl (C 3 ), 2-propynyl (C 3 ), 1-butynyl (C 4 ), 2-butynyl (C 4 ), and the like.
  • Examples of C 2-6 alkenyl groups include the aforementioned C 2-4 alkynyl groups as well as pentynyl (C 5 ), hexynyl (C 6 ), and the like. Additional examples of alkynyl include heptynyl (C 7 ), octynyl (C 8 ), and the like.
  • each instance of an alkynyl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkynyl”) or substituted (a “substituted alkynyl”) with one or more substituents.
  • the alkynyl group is unsubstituted C 2-10 alkynyl.
  • the alkynyl group is substituted C 2-10 alkynyl.
  • Carbocyclyl or “carbocyclic” refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms (“C 3-10 carbocyclyl”) and zero heteroatoms in the non-aromatic ring system.
  • a carbocyclyl group has 3 to 8 ring carbon atoms (“C 3-8 carbocyclyl”).
  • a carbocyclyl group has 3 to 6 ring carbon atoms (“C 3-6 carbocyclyl”).
  • a carbocyclyl group has 3 to 6 ring carbon atoms (“C 3-6 carbocyclyl”).
  • a carbocyclyl group has 5 to 10 ring carbon atoms (“C 5-10 carbocyclyl”).
  • Exemplary C 3-6 carbocyclyl groups include, without limitation, cyclopropyl (C 3 ), cyclopropenyl (C 3 ), cyclobutyl (C 4 ), cyclobutenyl (C 4 ), cyclopentyl (C 5 ), cyclopentenyl (C 5 ), cyclohexyl (C 6 ), cyclohexenyl (C 6 ), cyclohexadienyl (C 6 ), and the like.
  • Exemplary C 3-8 carbocyclyl groups include, without limitation, the aforementioned C 3-6 carbocyclyl groups as well as cycloheptyl (C 7 ), cycloheptenyl (C 7 ), cycloheptadienyl (C 7 ), cycloheptatrienyl (C 7 ), cyclooctyl (C 8 ), cyclooctenyl (C 8 ), bicyclo[2.2.1]heptanyl (C 7 ), bicyclo[2.2.2]octanyl (C 8 ), and the like.
  • Exemplary C 3-10 carbocyclyl groups include, without limitation, the aforementioned C 3-8 carbocyclyl groups as well as cyclononyl (C 9 ), cyclononenyl (C 9 ), cyclodecyl (C 10 ), cyclodecenyl (C 10 ), octahydro-1H-indenyl (C 9 ), decahydronaphthalenyl (C 10 ), spiro[4.5]decanyl (C 10 ), and the like.
  • the carbocyclyl group is either monocyclic (“monocyclic carbocyclyl”) or contain a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic carbocyclyl”) and can be saturated or can be partially unsaturated.
  • “Carbocyclyl” also includes ring systems wherein the carbocyclic ring, as defined above, is fused with one or more aryl or heteroaryl groups wherein the point of attachment is on the carbocyclic ring, and in such instances, the number of carbons continue to designate the number of carbons in the carbocyclic ring system.
  • each instance of a carbocyclyl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted carbocyclyl”) or substituted (a “substituted carbocyclyl”) with one or more substituents.
  • the carbocyclyl group is unsubstituted C 3-10 carbocyclyl.
  • the carbocyclyl group is substituted C 3-10 carbocyclyl.
  • “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 10 ring carbon atoms (“C 3-10 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“C 3-8 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C 3-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (“C 5-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (“C 5-10 cycloalkyl”).
  • C 5-6 cycloalkyl groups include cyclopentyl (C 5 ) and cyclohexyl (C 5 ).
  • Examples of C 3-6 cycloalkyl groups include the aforementioned C 5-6 cycloalkyl groups as well as cyclopropyl (C 3 ) and cyclobutyl (C 4 ).
  • Examples of C 3-8 cycloalkyl groups include the aforementioned C 3-6 cycloalkyl groups as well as cycloheptyl (C 7 ) and cyclooctyl (C 8 ).
  • each instance of a cycloalkyl group is independently unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents.
  • the cycloalkyl group is unsubstituted C 3-10 cycloalkyl.
  • the cycloalkyl group is substituted C 3-10 cycloalkyl.
  • Heterocyclyl or “heterocyclic” refers to a radical of a 3- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“3-10 membered heterocyclyl”).
  • the point of attachment can be a carbon or nitrogen atom, as valency permits.
  • a heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or a fused, bridged, or spiro ring system, such as a bicyclic system (“bicyclic heterocyclyl”), and can be saturated or can be partially unsaturated.
  • Heterocyclyl bicyclic ring systems can include one or more heteroatoms in one or both rings.
  • Heterocyclyl also includes ring systems wherein the heterocyclic ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclic ring, or ring systems wherein the heterocyclic ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclic ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclic ring system.
  • each instance of heterocyclyl is independently optionally substituted, i.e., unsubstituted (an “unsubstituted heterocyclyl”) or substituted (a “substituted heterocyclyl”) with one or more substituents.
  • the heterocyclyl group is unsubstituted 3-10 membered heterocyclyl. In certain embodiments, the heterocyclyl group is substituted 3-10 membered heterocyclyl.
  • a heterocyclyl group is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“5-10 membered heterocyclyl”).
  • a heterocyclyl group is a 5-8 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heterocyclyl”).
  • a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heterocyclyl”).
  • the 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
  • the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
  • the 5-6 membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
  • Exemplary 3-membered heterocyclyl groups containing one heteroatom include, without limitation, azirdinyl, oxiranyl, thiiranyl.
  • Exemplary 4-membered heterocyclyl groups containing one heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl.
  • Exemplary 5-membered heterocyclyl groups containing one heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione.
  • Exemplary 5-membered heterocyclyl groups containing two heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one.
  • Exemplary 5-membered heterocyclyl groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl.
  • Exemplary 6-membered heterocyclyl groups containing one heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl.
  • Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, without limitation, triazinanyl. Exemplary 7-membered heterocyclyl groups containing one heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8-membered heterocyclyl groups containing one heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl.
  • Exemplary 5-membered heterocyclyl groups fused to a C 6 aryl ring include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like.
  • Exemplary 6-membered heterocyclyl groups fused to an aryl ring include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
  • Aryl refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 pi electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“C 6-14 aryl”).
  • an aryl group has six ring carbon atoms (“C 6 aryl”; e.g., phenyl).
  • an aryl group has ten ring carbon atoms (“C 10 aryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl).
  • an aryl group has fourteen ring carbon atoms (“C 14 aryl”; e.g., anthracyl).
  • Aryl also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system.
  • each instance of an aryl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted aryl”) or substituted (a “substituted aryl”) with one or more substituents.
  • the aryl group is unsubstituted C 6-14 aryl.
  • the aryl group is substituted C 6-14 aryl.
  • Alkyl is a subset of alkyl and aryl and refers to an optionally substituted alkyl group substituted by an optionally substituted aryl group. In certain embodiments, the aralkyl is optionally substituted benzyl. In certain embodiments, the aralkyl is benzyl. In certain embodiments, the aralkyl is optionally substituted phenethyl. In certain embodiments, the aralkyl is phenethyl.
  • Heteroaryl refers to a radical of a 5-10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 pi electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“5-10 membered heteroaryl”).
  • heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits.
  • Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings.
  • Heteroaryl includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system. “Heteroaryl” also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused (aryl/heteroaryl) ring system.
  • Bicyclic heteroaryl groups wherein one ring does not contain a heteroatom e.g., indolyl, quinolinyl, carbazolyl, and the like
  • the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl).
  • a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heteroaryl”).
  • a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heteroaryl”).
  • a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heteroaryl”).
  • the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
  • the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
  • the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.
  • each instance of a heteroaryl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted heteroaryl”) or substituted (a “substituted heteroaryl”) with one or more substituents.
  • the heteroaryl group is unsubstituted 5-14 membered heteroaryl. In certain embodiments, the heteroaryl group is substituted 5-14 membered heteroaryl.
  • Exemplary 5-membered heteroaryl groups containing one heteroatom include, without limitation, pyrrolyl, furanyl, and thiophenyl.
  • Exemplary 5-membered heteroaryl groups containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl.
  • Exemplary 5-membered heteroaryl groups containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl.
  • Exemplary 5-membered heteroaryl groups containing four heteroatoms include, without limitation, tetrazolyl.
  • Exemplary 6-membered heteroaryl groups containing one heteroatom include, without limitation, pyridinyl.
  • Exemplary 6-membered heteroaryl groups containing two heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl.
  • Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively.
  • Exemplary 7-membered heteroaryl groups containing one heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl.
  • Exemplary 5,6-bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl.
  • Exemplary 6,6-bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
  • Heteroaralkyl is a subset of alkyl and heteroaryl and refers to an optionally substituted alkyl group substituted by an optionally substituted heteroaryl group.
  • “Unsaturated” or “partially unsaturated” refers to a group that includes at least one double or triple bond.
  • a “partially unsaturated” ring system is further intended to encompass rings having multiple sites of unsaturation, but is not intended to include aromatic groups (e.g., aryl or heteroaryl groups).
  • “saturated” refers to a group that does not contain a double or triple bond, i.e., contains all single bonds.
  • Alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups, which are divalent bridging groups, are further referred to using the suffix -ene, e.g., alkylene, alkenylene, alkynylene, carbocyclylene, heterocyclylene, arylene, and heteroarylene.
  • An atom, moiety, or group described herein may be unsubstituted or substituted, as valency permits, unless otherwise provided expressly.
  • the term “optionally substituted” refers to substituted or unsubstituted.
  • alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups are optionally substituted (e.g., “substituted” or “unsubstituted” alkyl, “substituted” or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl, “substituted” or “unsubstituted” carbocyclyl, “substituted” or “unsubstituted” heterocyclyl, “substituted” or “unsubstituted” aryl, or “substituted” or “unsubstituted” heteroaryl group).
  • substituted means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction.
  • a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position.
  • substituted is contemplated to include substitution with all permissible substituents of organic compounds, any of the substituents described herein that results in the formation of a stable compound.
  • the present disclosure contemplates any and all such combinations in order to arrive at a stable compound.
  • heteroatoms such as nitrogen may have hydrogen substituents and/or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety.
  • the substituent is a carbon atom substituent.
  • the substituent is a nitrogen atom substituent.
  • the substituent is an oxygen atom substituent.
  • the substituent is a sulfur atom substituent.
  • Exemplary carbon atom substituents include, but are not limited to, halogen, —CN, —NO 2 , —N 3 , —SO 2 H, —SO 3 H, —OH, —OR aa , —ON(R bb ) 2 , —N(R bb ) 2 , —N(R bb ) 3 + X ⁇ , —N(OR cc )R bb , —SH, —SR aa , —SSR cc , —C( ⁇ O)R aa , —CO 2 H, —CHO, —C(OR cc ) 2 , —CO 2 R aa , —OC( ⁇ O)R aa , —OCO 2 R aa , —C( ⁇ O)N(R bb ) 2 , —OC( ⁇ O)N(R bb ) 2 , —NR bb C
  • each instance of R aa is, independently, selected from C 1-10 alkyl, C 1-10 perhaloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, and 5-14 membered heteroaryl, or two R aa groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups;
  • each instance of R bb is, independently, selected from hydrogen, —OH, —OR aa , —N(R cc ) 2 , —CN, —C( ⁇ O)R aa , —C( ⁇ O)N(R cc ) 2 , —CO 2 R aa , —SO 2 R aa , —C( ⁇ NR cc )OR aa , —C( ⁇ NR cc )N(R cc ) 2 , —SO 2 N(R cc ) 2 , —SO 2 R cc , —SO 2 OR cc , —SOR aa , —C( ⁇ S)N(R cc ) 2 , —C( ⁇ O)SR cc , —C( ⁇ S)SR cc , —P( ⁇ O)(R aa ) 2 , —P( ⁇ O)(OR cc ) 2
  • each instance of R cc is, independently, selected from hydrogen, C 1-10 alkyl, C 1-10 perhaloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, and 5-14 membered heteroaryl, or two R cc groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups;
  • each instance of R dd is, independently, selected from halogen, —CN, —NO 2 , —N 3 , —SO 2 H, —SO 3 H, —OH, —OR ee , —ON(R ff ) 2 , —N(R ff ) 2 , —N(R ff ) 3 + X ⁇ , —N(OR ee )R ff , —SH, —SR ee , —SSR ee , —C( ⁇ O)R ee , —CO 2 H, —CO 2 R ee , —OC( ⁇ O)R ee , —OCO 2 R ee , —C( ⁇ O)N(R ff ) 2 , —OC( ⁇ O)N(R ff ) 2 , —NR ff ( ⁇ O)R ee , —NR ff CO 2 R e
  • each instance of R ee is, independently, selected from C 1-6 alkyl, C 1-6 perhaloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 carbocyclyl, C 6-10 aryl, 3-10 membered heterocyclyl, and 3-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R gg groups;
  • each instance of R ff is, independently, selected from hydrogen, C 1-6 alkyl, C 1-6 perhaloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 carbocyclyl, 3-10 membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl, or two R ff groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R gg groups; and
  • each instance of R gg is, independently, halogen, —CN, —NO 2 , —N 3 , —SO 2 H, —SO 3 H, —OH, —OC 1-6 alkyl, —ON(C 1-6 alkyl) 2 , —N(C 1-6 alkyl) 2 , —N(C 1-6 alkyl) 3 + X ⁇ , —NH(C 1-6 alkyl) 2 + X ⁇ , —NH 2 (C 1-6 alkyl) + X ⁇ , —NH 3 + X ⁇ , —N(OC 1-6 alkyl)(C 1-6 alkyl), —N(OH)(C 1-6 alkyl), —NH(OH), —SH, —SC 1-6 alkyl, —SS(C 1-6 alkyl), —C( ⁇ O)(C 1-6 alkyl), —CO 2 H, —CO 2 (C 1 alkyl), —OC( ⁇ O)(
  • a “counterion” or “anionic counterion” is a negatively charged group associated with a positively charged group in order to maintain electronic neutrality.
  • An anionic counterion may be monovalent (i.e., including one formal negative charge).
  • An anionic counterion may also be multivalent (i.e., including more than one formal negative charge), such as divalent or trivalent.
  • Exemplary counterions include halide ions (e.g., F ⁇ , Cl ⁇ , Br ⁇ , F ⁇ ), NO 3 ⁇ , ClO 4 ⁇ , OH ⁇ , H 2 PO 4 ⁇ , HSO 4 ⁇ , sulfonate ions (e.g., methansulfonate, trifluoromethanesulfonate, p-toluenesulfonate, benzenesulfonate, 10-camphor sulfonate, naphthalene-2-sulfonate, naphthalene-1-sulfonic acid-5-sulfonate, ethan-1-sulfonic acid-2-sulfonate, and the like), carboxylate ions (e.g., acetate, propanoate, benzoate, glycerate, lactate, tartrate, glycolate, gluconate, and the like), BF 4 ⁇ , PF 4
  • Exemplary counterions which may be multivalent include CO 3 2 ⁇ , HPO 4 2 ⁇ , PO 4 3 ⁇ , B 4 O 7 2 ⁇ , SO 4 2 ⁇ , S 2 O 3 2 ⁇ , carboxylate anions (e.g., tartrate, citrate, fumarate, maleate, malate, malonate, gluconate, succinate, glutarate, adipate, pimelate, suberate, azelate, sebacate, salicylate, phthalates, aspartate, glutamate, and the like), and carboranes.
  • carboxylate anions e.g., tartrate, citrate, fumarate, maleate, malate, malonate, gluconate, succinate, glutarate, adipate, pimelate, suberate, azelate, sebacate, salicylate, phthalates, aspartate, glutamate, and the like
  • carboranes e.g., tartrate, citrate, fumarate, maleate, mal
  • Halo or “halogen” refers to fluorine (fluoro, —F), chlorine (chloro, —Cl), bromine (bromo, —Br), or iodine (iodo, —I).
  • “Acyl” refers to a moiety selected from the group consisting of —C( ⁇ O)R aa , —CHO, —CO 2 R aa , —C( ⁇ O)N(R bb ) 2 , —C( ⁇ NR bb )R aa , —C( ⁇ NR bb )OR aa , —C( ⁇ NR bb )N(R bb ) 2 , —C( ⁇ O)NR bb SO 2 R aa , —C( ⁇ S)N(R bb ) 2 , —C( ⁇ O)SR aa , or —C( ⁇ S)SR aa , wherein R aa and R bb are as defined herein.
  • Nitrogen atoms can be substituted or unsubstituted as valency permits, and include primary, secondary, tertiary, and quaternary nitrogen atoms.
  • Exemplary nitrogen atom substituents include, but are not limited to, hydrogen, —OH, —OR aa , —N(R cc ) 2 , —CN, —C( ⁇ O)R aa , —C( ⁇ O)N(R cc ) 2 , —CO 2 R aa , —SO 2 R aa , —C( ⁇ NR bb )R aa , —C( ⁇ NR cc )OR aa , —C( ⁇ NR cc )N(R cc ) 2 , —SO 2 N(R cc ) 2 , —SO 2 R cc , —SO 2 OR cc , —SOR aa , —C( ⁇ S)N(R
  • the substituent present on a nitrogen atom is a nitrogen protecting group (also referred to as an amino protecting group).
  • Nitrogen protecting groups include, but are not limited to, —OH, —OR aa , —N(R cc ) 2 , —C( ⁇ O)R aa , —C( ⁇ O)N(R cc ) 2 , —CO 2 R aa , —SO 2 R aa , —C( ⁇ NR cc )R aa , —C( ⁇ NR cc )OR aa , —C( ⁇ NR cc )N(R cc ) 2 , —SO 2 N(R cc ) 2 , —SO 2 R cc , —SO 2 OR cc , —SOR aa , —C( ⁇ S)N(R cc ) 2 , —C( ⁇ O)SR cc , —C(C(
  • Nitrogen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis , T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
  • nitrogen protecting groups such as amide groups (e.g., —C( ⁇ O)R aa ) include, but are not limited to, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl derivative, benzamide, p-phenylbenzamide, o-nitophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (N′-dithiobenzyloxyacylamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitro
  • Nitrogen protecting groups such as carbamate groups include, but are not limited to, methyl carbamate, ethyl carbamate, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluoroenylmethyl carbamate, 2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1-methylethyl carbamate
  • Nitrogen protecting groups such as sulfonamide groups include, but are not limited to, p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6,-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide
  • Ts p-toluenesulfonamide
  • nitrogen protecting groups include, but are not limited to, phenothiazinyl-(10)-acyl derivative, N′-p-toluenesulfonylaminoacyl derivative, N′-phenylaminothioacyl derivative, N-benzoylphenylalanyl derivative, N-acetylmethionine derivative, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N-1,1,4,4-tetramethyldisilylazacyclopentane adduct (STABASE), 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4
  • oxygen atom substituents include, but are not limited to, —R aa , —C( ⁇ O)SR aa , —C( ⁇ O)R aa , —CO 2 R aa , —C( ⁇ O)N(R bb ) 2 , —C( ⁇ NR bb )R aa , —C( ⁇ NR bb )OR aa , —C( ⁇ NR bb )N(R bb ) 2 , —S( ⁇ O)R aa , —SO 2 R aa , —Si(R aa ) 3 , —P(R cc ) 2 , —P(R cc ) 3 + X ⁇ , —P(OR cc ) 2 , —P(OR cc ) 3 + X ⁇ , —P(OR cc ) 2 , —P(OR cc )
  • the oxygen atom substituent present on an oxygen atom is an oxygen protecting group (also referred to as a hydroxyl protecting group).
  • Oxygen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis , T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
  • oxygen protecting groups include, but are not limited to, methyl, t-butyloxycarbonyl (BOC or Boc), methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), t-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-me
  • Exemplary sulfur atom substituents include, but are not limited to, —R aa , —C( ⁇ O)SR aa , —C( ⁇ O)R aa , —CO 2 R aa , —C( ⁇ O)N(R bb ) 2 , —C( ⁇ NR bb )R aa , —C( ⁇ NR bb )OR aa , —C( ⁇ NR bb )N(R bb ) 2 , —S( ⁇ O)R aa , —SO 2 R aa , —Si(R aa ) 3 , —P(R cc ) 2 , —P(R cc ) 3 + X ⁇ , —P(OR cc ) 2 , —P(OR cc ) 3 + X ⁇ , —P(OR cc ) 2 , —P(OR cc
  • the sulfur atom substituent present on a sulfur atom is a sulfur protecting group (also referred to as a thiol protecting group).
  • Sulfur protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis , T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
  • leaving group is given its ordinary meaning in the art of synthetic organic chemistry and refers to an atom or a group capable of being displaced by a nucleophile. See, for example, Smith, March Advanced Organic Chemistry 6th ed. (501-502).
  • Suitable leaving groups include, but are not limited to, halogen (such as F, Cl, Br, or I (iodine)), alkoxycarbonyloxy, aryloxycarbonyloxy, alkanesulfonyloxy, arenesulfonyloxy, alkyl-carbonyloxy (e.g., acetoxy), arylcarbonyloxy, aryloxy, methoxy, N,O-dimethylhydroxylamino, pixyl, and haloformates.
  • halogen such as F, Cl, Br, or I (iodine
  • the leaving group is an activated substituted hydroxyl group (e.g., —OC( ⁇ O)SR aa , —OC( ⁇ O)R aa , —OCO 2 R aa , —OC( ⁇ O)N(R bb ) 2 , —OC( ⁇ NR bb )R aa , —OC( ⁇ NR bb )OR aa , —OC( ⁇ NR bb )N(R bb ) 2 , —OS( ⁇ O)R aa , —OSO 2 R aa , —OP(R cc ) 2 , —OP(R cc ) 3 , —OP( ⁇ O) 2 R aa , —OP( ⁇ O)(R aa ) 2 , —OP( ⁇ O)(OR cc ) 2 , —OP( ⁇ O) 2 N(R bb ) 2 , and —OP( ⁇ O
  • the leaving group is a sulfonic acid ester, such as toluenesulfonate (tosylate, —OTs), methanesulfonate (mesylate, —OMs), p-bromobenzenesulfonyloxy (brosylate, —OBs), —OS( ⁇ O) 2 (CF 2 ) 3 CF 3 (nonaflate, —ONf), or trifluoromethanesulfonate (triflate, —OTf).
  • the leaving group is a brosylate, such as p-bromobenzenesulfonyloxy.
  • the leaving group is a nosylate, such as 2-nitrobenzenesulfonyloxy. In some embodiments, the leaving group is a sulfonate-containing group. In some embodiments, the leaving group is a tosylate group.
  • the leaving group may also be a phosphineoxide (e.g., formed during a Mitsunobu reaction) or an internal leaving group such as an epoxide or cyclic sulfate.
  • Other non-limiting examples of leaving groups are water, ammonia, alcohols, ether moieties, thioether moieties, zinc halides, magnesium moieties, diazonium salts, and copper moieties.
  • pharmaceutically acceptable salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference.
  • Pharmaceutically acceptable salts of the compounds described herein include those derived from suitable inorganic and organic acids and bases.
  • Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods known in the art such as ion exchange.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid
  • organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods known in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
  • Salts derived from appropriate bases include alkali metal, alkaline earth metal, and ammonium salts.
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.
  • solvate refers to forms of the compound, or a salt thereof, that are associated with a solvent, usually by a solvolysis reaction. This physical association may include hydrogen bonding.
  • Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, diethyl ether, and the like.
  • the compounds described herein may be prepared, e.g., in crystalline form, and may be solvated.
  • Suitable solvates include pharmaceutically acceptable solvates and further include both stoichiometric solvates and non-stoichiometric solvates. In certain instances, the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the crystal lattice of a crystalline solid.
  • “Solvate” encompasses both solution-phase and isolatable solvates. Representative solvates include hydrates, ethanolates, and methanolates.
  • hydrate refers to a compound that is associated with water.
  • the number of the water molecules contained in a hydrate of a compound is in a definite ratio to the number of the compound molecules in the hydrate. Therefore, a hydrate of a compound may be represented, for example, by the general formula R ⁇ x H 2 O, wherein R is the compound, and x is a number greater than 0.
  • a given compound may form more than one type of hydrate, including, e.g., monohydrates (x is 1), lower hydrates (x is a number greater than 0 and smaller than 1, e.g., hemihydrates (R ⁇ 0.5H 2 O)), and polyhydrates (x is a number greater than 1, e.g., dihydrates (R ⁇ 2 H 2 O) and hexahydrates (R ⁇ 6H 2 O)).
  • monohydrates x is 1
  • lower hydrates x is a number greater than 0 and smaller than 1, e.g., hemihydrates (R ⁇ 0.5H 2 O)
  • polyhydrates x is a number greater than 1, e.g., dihydrates (R ⁇ 2 H 2 O) and hexahydrates (R ⁇ 6H 2 O)
  • tautomers or “tautomeric” refers to two or more interconvertible compounds resulting from at least one formal migration of a hydrogen atom and at least one change in valency (e.g., a single bond to a double bond, a triple bond to a single bond, or vice versa).
  • the exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Tautomerizations (i.e., the reaction providing a tautomeric pair) may catalyzed by acid or base.
  • Exemplary tautomerizations include keto-to-enol, amide-to-imide, lactam-to-lactim, enamine-to-imine, and enamine-to-(a different enamine) tautomerizations.
  • stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers”.
  • enantiomers When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible.
  • An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or ( ⁇ )-isomers respectively).
  • a chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”.
  • polymorphs refers to a crystalline form of a compound (or a salt, hydrate, or solvate thereof). All polymorphs have the same elemental composition. Different crystalline forms usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. Recrystallization solvent, rate of crystallization, storage temperature, and other factors may cause one crystal form to dominate. Various polymorphs of a compound can be prepared by crystallization under different conditions.
  • prodrugs refers to compounds that have cleavable groups and become by solvolysis or under physiological conditions the compounds described herein, which are pharmaceutically active in vivo. Such examples include, but are not limited to, choline ester derivatives and the like, N-alkylmorpholine esters and the like. Other derivatives of the compounds described herein have activity in both their acid and acid derivative forms, but in the acid sensitive form often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, H., Design of Prodrugs , pp. 7-9, 21-24, Elsevier, Amsterdam 1985).
  • Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides, and anhydrides derived from acidic groups pendant on the compounds described herein are particular prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters.
  • C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, aryl, C 7 -C 12 substituted aryl, and C 7 -C 12 arylalkyl esters of the compounds described herein may be preferred.
  • small molecule refers to molecules, whether naturally-occurring or artificially created (e.g., via chemical synthesis) that have a relatively low molecular weight.
  • a small molecule is an organic compound (i.e., it contains carbon).
  • the small molecule may contain multiple carbon-carbon bonds, stereocenters, and other functional groups (e.g., amines, hydroxyl, carbonyls, and heterocyclic rings, etc.).
  • the molecular weight of a small molecule is not more than about 1,000 g/mol, not more than about 900 g/mol, not more than about 800 g/mol, not more than about 700 g/mol, not more than about 600 g/mol, not more than about 500 g/mol, not more than about 400 g/mol, not more than about 300 g/mol, not more than about 200 g/mol, or not more than about 100 g/mol.
  • the molecular weight of a small molecule is at least about 100 g/mol, at least about 200 g/mol, at least about 300 g/mol, at least about 400 g/mol, at least about 500 g/mol, at least about 600 g/mol, at least about 700 g/mol, at least about 800 g/mol, or at least about 900 g/mol, or at least about 1,000 g/mol. Combinations of the above ranges (e.g., at least about 200 g/mol and not more than about 500 g/mol) are also possible.
  • the small molecule is a therapeutically active agent such as a drug (e.g., a molecule approved by the U.S.
  • the small molecule may also be complexed with one or more metal atoms and/or metal ions.
  • Preferred small molecules are biologically active in that they produce a biological effect in animals, preferably mammals, more preferably humans.
  • Small molecules include, but are not limited to, radionuclides and imaging agents.
  • the small molecule is a drug.
  • the drug is one that has already been deemed safe and effective for use in humans or animals by the appropriate governmental agency or regulatory body. For example, drugs approved for human use are listed by the FDA under 21 C.F.R.
  • inhibitor refers to the ability of a compound to reduce, slow, halt, or prevent activity of a particular biological process (e.g., activity of Myc) in a cell relative to vehicle.
  • a compound, pharmaceutical composition, method, use, or kit When a compound, pharmaceutical composition, method, use, or kit is referred to as “selectively,” “specifically,” or “competitively” modulating (e.g., inhibiting) a Myc, the compound, pharmaceutical composition, method, use, or kit inhibits the Myc to a greater extent (e.g., not less than 2-fold, not less than 5-fold, not less than 10-fold, not less than 30-fold, not less than 100-fold, not less than 1,000-fold, or not less than 10,000-fold; and/or not more than 2-fold, not more than 5-fold, not more than 10-fold, not more than 30-fold, not more than 100-fold, not more than 1,000-fold, or not more than 10,000-fold) than inhibiting a different Myc and/or a different transcription factor.
  • a greater extent e.g., not less than 2-fold, not less than 5-fold, not less than 10-fold, not less than 30-fold, not less than 100-fold, not less than 1,000-fold,
  • aberrant activity refers to activity deviating from normal activity. In certain embodiments, the aberrant activity is increased activity. In certain embodiments, the aberrant activity is decreased activity.
  • increased activity refers to activity higher than normal activity. The term “decreased activity” refers to activity lower than normal activity.
  • composition and “formulation” are used interchangeably.
  • a “subject” to which administration is contemplated refers to a human (i.e., male or female of any age group, e.g., pediatric subject (e.g., infant, child, or adolescent) or adult subject (e.g., young adult, middle-aged adult, or senior adult)) or non-human animal.
  • the non-human animal is a mammal (e.g., primate (e.g., cynomolgus monkey or rhesus monkey), commercially relevant mammal (e.g., cattle, pig, horse, sheep, goat, cat, or dog), or bird (e.g., commercially relevant bird, such as chicken, duck, goose, or turkey)).
  • primate e.g., cynomolgus monkey or rhesus monkey
  • commercially relevant mammal e.g., cattle, pig, horse, sheep, goat, cat, or dog
  • bird e.g., commercially relevant bird, such as
  • the non-human animal is a fish, reptile, or amphibian.
  • the non-human animal may be a male or female at any stage of development.
  • the non-human animal may be a transgenic animal or genetically engineered animal.
  • a “patient” refers to a human subject in need of treatment of a disease (e.g., proliferative disease).
  • tissue sample refers to any sample including tissue samples (such as tissue sections and needle biopsies of a tissue); cell samples (e.g., cytological smears (such as Pap or blood smears) or samples of cells obtained by microdissection); samples of whole organisms (such as samples of yeasts or bacteria); or cell fractions, fragments or organelles (such as obtained by lysing cells and separating the components thereof by centrifugation or otherwise).
  • tissue samples such as tissue sections and needle biopsies of a tissue
  • cell samples e.g., cytological smears (such as Pap or blood smears) or samples of cells obtained by microdissection) or samples of cells obtained by microdissection
  • samples of whole organisms such as samples of yeasts or bacteria
  • cell fractions, fragments or organelles such as obtained by lysing cells and separating the components thereof by centrifugation or otherwise.
  • biological samples include blood, serum, urine, semen, fecal matter, cerebrospinal fluid, interstitial fluid, mucous, tears, sweat, pus, biopsied tissue (e.g., obtained by a surgical biopsy or needle biopsy), nipple aspirates, milk, vaginal fluid, saliva, swabs (such as buccal swabs), or any material containing biomolecules that is derived from a first biological sample.
  • administer refers to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing a compound described herein, or a composition thereof, in or on a subject.
  • treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease described herein.
  • treatment may be administered after one or more signs or symptoms of the disease have developed or have been observed.
  • treatment may be administered in the absence of signs or symptoms of the disease.
  • treatment may be administered to a susceptible subject prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of exposure to a pathogen). Treatment may also be continued after symptoms have resolved, for example, to delay or prevent recurrence.
  • prevent refers to a prophylactic treatment of a subject who is not and was not with a disease but is at risk of developing the disease or who was with a disease, is not with the disease, but is at risk of regression of the disease.
  • the subject is at a higher risk of developing the disease or at a higher risk of regression of the disease than an average healthy member of a population.
  • an “effective amount” of a compound described herein refers to an amount sufficient to elicit the desired biological response.
  • An effective amount of a compound described herein may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject.
  • an effective amount is a therapeutically effective amount.
  • an effective amount is a prophylactic treatment.
  • an effective amount is the amount of a compound described herein in a single dose.
  • an effective amount is the combined amounts of a compound described herein in multiple doses.
  • a “therapeutically effective amount” of a compound described herein is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or to delay or minimize one or more symptoms associated with the condition.
  • a therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the condition.
  • the term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms, signs, or causes of the condition, and/or enhances the therapeutic efficacy of another therapeutic agent.
  • a therapeutically effective amount is effective for modulating (e.g., inhibiting) the activity of Myc.
  • a therapeutically effective amount is effective for treating a disease (e.g., proliferative disease).
  • a therapeutically effective amount is effective for modulating (e.g., inhibiting) the activity of Myc and effective for treating a disease (e.g., proliferative disease).
  • a “prophylactically effective amount” of a compound described herein is an amount sufficient to prevent a condition, or one or more symptoms associated with the condition or prevent its recurrence.
  • a prophylactically effective amount of a compound means an amount of a therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the condition.
  • the term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
  • a prophylactically effective amount is effective for modulating (e.g., inhibiting) the activity of Myc.
  • a prophylactically effective amount is effective for preventing a disease (e.g., proliferative disease). In certain embodiments, a prophylactically effective amount is effective for modulating (e.g., inhibiting) the activity of Myc and effective for preventing a disease (e.g., proliferative disease).
  • transcription factor refers to is a protein that binds to specific DNA sequences, thereby controlling the rate of transcription of genetic information from DNA to messenger RNA. Transcription factors perform their functions alone or with other proteins in a complex, by promoting (as an activator), or blocking (as a repressor) the recruitment of RNA polymerase to specific genes.
  • a feature of transcription factors is that they contain one or more DNA-binding domains (DBDs), which attach to specific sequences of DNA adjacent to the genes that they regulate.
  • DBDs DNA-binding domains
  • a transcription factor described herein is Myc.
  • a transcription factor described herein is c-Myc.
  • a transcription factor described herein is Mad.
  • a transcription factor described herein is Mxi1.
  • a transcription factor described herein is SP1, AP-1, C/EBP, heat shock factor, ATF/CREB, Oct-1, or NF-1.
  • Myc refers to the Myc family of transcription factors and the genes encoding the Myc family of transcription factors.
  • the Myc is c-Myc (encoded by the MYC gene (HomoloGene: 31092; ChEMBL: 1250348; GeneCards: MYC Gene)).
  • the Myc is L-Myc (encoded by the MYCL gene (HomoloGene: 3921; GeneCards: MYCL Gene)) or N-Myc (encoded by the MYCN gene (HomoloGene: 3922; GeneCards: MYCN Gene)).
  • the Myc is MYC.
  • the Myc is MYCL or MYCN.
  • proliferative disease refers to a disease that occurs due to abnormal growth or extension by the multiplication of cells (Walker, Cambridge Dictionary of Biology ; Cambridge University Press: Cambridge, UK, 1990).
  • a proliferative disease may be associated with: 1) the pathological proliferation of normally quiescent cells; 2) the pathological migration of cells from their normal location (e.g., metastasis of neoplastic cells); 3) the pathological expression of proteolytic enzymes such as the matrix metalloproteinases (e.g., collagenases, gelatinases, and elastases); or 4) the pathological angiogenesis as in proliferative retinopathy and tumor metastasis.
  • Exemplary proliferative diseases include cancers (i.e., “malignant neoplasms”), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases.
  • angiogenesis refers to the physiological process through which new blood vessels form from pre-existing vessels.
  • Angiogenesis is distinct from vasculogenesis, which is the de novo formation of endothelial cells from mesoderm cell precursors. The first vessels in a developing embryo form through vasculogenesis, after which angiogenesis is responsible for most blood vessel growth during normal or abnormal development.
  • Angiogenesis is a vital process in growth and development, as well as in wound healing and in the formation of granulation tissue.
  • angiogenesis is also a fundamental step in the transition of tumors from a benign state to a malignant one, leading to the use of angiogenesis inhibitors in the treatment of cancer.
  • Angiogenesis may be chemically stimulated by angiogenic proteins, such as growth factors (e.g., VEGF).
  • angiogenic proteins such as growth factors (e.g., VEGF).
  • VEGF growth factors
  • “Pathological angiogenesis” refers to abnormal (e.g., excessive or insufficient) angiogenesis that amounts to and/or is associated with a disease.
  • neoplasm and “tumor” are used herein interchangeably and refer to an abnormal mass of tissue wherein the growth of the mass surpasses and is not coordinated with the growth of a normal tissue.
  • a neoplasm or tumor may be “benign” or “malignant,” depending on the following characteristics: degree of cellular differentiation (including morphology and functionality), rate of growth, local invasion, and metastasis.
  • a “benign neoplasm” is generally well differentiated, has characteristically slower growth than a malignant neoplasm, and remains localized to the site of origin.
  • a benign neoplasm does not have the capacity to infiltrate, invade, or metastasize to distant sites.
  • Exemplary benign neoplasms include, but are not limited to, lipoma, chondroma, adenomas, acrochordon, senile angiomas, seborrheic keratoses, lentigos, and sebaceous hyperplasias.
  • certain “benign” tumors may later give rise to malignant neoplasms, which may result from additional genetic changes in a subpopulation of the tumor's neoplastic cells, and these tumors are referred to as “pre-malignant neoplasms.”
  • An exemplary pre-malignant neoplasm is a teratoma.
  • a “malignant neoplasm” is generally poorly differentiated (anaplasia) and has characteristically rapid growth accompanied by progressive infiltration, invasion, and destruction of the surrounding tissue. Furthermore, a malignant neoplasm generally has the capacity to metastasize to distant sites.
  • the term “metastasis,” “metastatic,” or “metastasize” refers to the spread or migration of cancerous cells from a primary or original tumor to another organ or tissue and is typically identifiable by the presence of a “secondary tumor” or “secondary cell mass” of the tissue type of the primary or original tumor and not of that of the organ or tissue in which the secondary (metastatic) tumor is located.
  • a prostate cancer that has migrated to bone is said to be metastasized prostate cancer and includes cancerous prostate cancer cells growing in bone tissue.
  • cancer refers to a class of diseases characterized by the development of abnormal cells that proliferate uncontrollably and have the ability to infiltrate and destroy normal body tissues. See, e.g., Stedman's Medical Dictionary, 25th ed.; Hensyl ed.; Williams & Wilkins: Philadelphia, 1990.
  • Exemplary cancers include, but are not limited to, hematological malignancies. Additional exemplary cancers include, but are not limited to, lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung); kidney cancer (e.g., nephroblastoma, a.k.a.
  • Wilms' tumor, renal cell carcinoma acoustic neuroma; adenocarcinoma; adrenal gland cancer; anal cancer; angiosarcoma (e.g., lymphangiosarcoma, lymphangioendotheliosarcoma, hemangiosarcoma); appendix cancer; benign monoclonal gammopathy; biliary cancer (e.g., cholangiocarcinoma); bladder cancer; breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast); brain cancer (e.g., meningioma, glioblastomas, glioma (e.g., astrocytoma, oligodendroglioma), medulloblastoma); bronchus cancer; carcinoid tumor; cervical cancer (e.g., cervical adenocarcinoma); choriocarcinoma
  • myelofibrosis MF
  • chronic idiopathic myelofibrosis chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)
  • neuroblastoma e.g., neurofibromatosis (NF) type 1 or type 2, schwannomatosis
  • neuroendocrine cancer e.g., gastroenteropancreatic neuroendoctrine tumor (GEP-NET), carcinoid tumor
  • osteosarcoma e.g., bone cancer
  • ovarian cancer e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma
  • papillary adenocarcinoma pancreatic cancer
  • pancreatic cancer e.g., pancreatic andenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), Islet cell tumors
  • hematological malignancy refers to tumors that affect blood, bone marrow, and/or lymph nodes.
  • exemplary hematological malignancies include, but are not limited to, leukemia, such as acute lymphocytic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myelocytic leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myelocytic leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL)); lymphoma, such as Hodgkin lymphoma (HL) (e.g., B-cell HL, T-cell HL) and non-Hodgkin lymphoma (NHL) (e.g., B-cell NHL, such as diffuse large cell lymphoma (DLCL) (e.
  • FIG. 1A shows the chemical structure of Compound 1.
  • FIG. 1B shows exemplary results of Compound 1 in an initial reporter assay.
  • FIG. 2 shows exemplary results of a cell viability assay of Compound 1.
  • Compound 1 affected cell viability after treatment with Compound 1 for 3 days (and 4 days for GBM4 and NHA), as measured using CELL TITER GLO (Promega) in 4 different cancer cell lines: ST486 (Burkitt's lymphoma; FIG. 2 ), CA46 (Burkitt's lymphoma; FIG. 2 ), NCI-H1963 (small cell lung cancer; FIG. 2 ), and GBM4 (glioblastoma; FIG. 2 ).
  • FIGS. 3A to 3B show exemplary results of an assay of cell viability and the selectivity of Compound 1 for cells expressing Myc and non-Myc expressing cells.
  • RLU Relative Luminescence Units.
  • FIGS. 4A to 4B show exemplary Western blotting results of Compound 1-mediated pull downs of MAX where free Compound 1 is used as a soluble competitor.
  • Compound 5 beads FIGS. 4A-4B ) were used.
  • the structure of Compound 5 is:
  • FIGS. 5A to 5B show the synthesis of KI-MS2-008 and proposed retrosynthetic schemes for making synthetic analogues.
  • FIG. 6 shows proteins visualized by immunoblotting (c-Myc: 9E10, Santa Cruz Biotechnology; Max: C-124, Santa Cruz Biotechnology).
  • KI-MS2-081 loaded beads pulled down significantly more c-Myc and Max compared to empty beads when 2 or 4 mg of total protein were incubated with beads.
  • P493-6 cells were washed twice with cold PBS and resuspended in modified RIPA buffer (200 mM NaCl, 50 mM Tris, 1% NP-40, 0.1 g/100 mL sodium deoxycholate, protease inhibitor cocktail, phosphatase inhibitor, 0.4 ⁇ L benzonase per 10 mL buffer, pH 7.5) at a density of about 50 million cells per mL of modified RIPA buffer. Cell resuspensions were vortexed briefly and left on ice for 20 min. The mixture was spun down at 14,000 g for 10 min at 4° C. The supernatant following centrifugation was the whole cell lysate.
  • modified RIPA buffer 200 mM NaCl, 50 mM Tris, 1% NP-40, 0.1 g/100 mL sodium deoxycholate, protease inhibitor cocktail, phosphatase inhibitor, 0.4 ⁇ L benzonase per 10 mL buffer, pH 7.5
  • Protein concentrations were estimated via Bradford assay and the same amount of lysate was incubated with either KI-MS2-081 loaded beads or empty beads at 4° C. for 1 hour. Beads were collected and washed three times with 500 ⁇ L wash buffer. Finally, proteins were eluted off of beads with 50 ⁇ L of 2 ⁇ Laemmli sample buffer with 2-mercaptoethanol and boiling at 90° C. for 1 hour. Proteins were visualized by immunoblotting (c-Myc: 9E10, Santa Cruz Biotechnology; Max: C-124, Santa Cruz Biotechnology). KI-MS2-081 loaded beads pulled down significantly more c-Myc and Max compared to empty beads when 2 or 4 mg of total protein were incubated with beads.
  • FIG. 7 shows an overview of a target engagement study in live cells using KI-MS2-085.
  • Cells were treated with a biologically active photoprobe followed by irradiation and installation of Alexa Fluor 647 azide or biotin azide via click chemistry and were analyzed by fluorescence or enriched and analyzed by western-blot.
  • Alexa Fluor 647 azide or biotin azide via click chemistry and were analyzed by fluorescence or enriched and analyzed by western-blot.
  • the diazirine alkyne analogue KI-MS2-085 retained cellular activity and was further utilized in the target engagement studies.
  • FIGS. 8A to 8B show target engagement in live cells using KI-MS2-085 clicked on AlexaFluor.
  • An inactive benzophenone (KI-MS2-073) and an active diazirine compound (KI-MS2-085) are shown in FIG. 8A .
  • Clicking on AlexaFluor to KI-MS2-085 illuminates a 20 kDa band in live cell treatments.
  • the active compound illuminates two bands at 20 kDa, which is the molecular weight of two Max isoforms. These bands overlap with western blot detection of Max ( FIG. 8B ).
  • the interaction is competed when 20 ⁇ M soluble KI-MS2-008 compound is present. Another non-selective band appears for both the active and inactive analogues.
  • FIGS. 9A to 9B show target engagement in live cells using KI-MS2-085 clicked on Biotin with Streptavidin Enrichment. Clicking on Biotin to KI-MS2-085 followed by Streptavidin enrichment yielded Max protein enrichment by western-blot ( FIG. 9A ). A coomassie total protein stain is also shown ( FIG. 9B ).
  • FIG. 10 shows a general schematic for Co—IP MS experiment to investigate mechanism of action of KI-MS2-008: Whole cell lysate was generated and a Max-anchored co-immunoprecipitation was performed when KI-MS2-008 was or was not added to the cell lysate. Proteins bound to anti-Max beads were identified via mass spec with tandem mass tagging (TMT) based quantification.
  • TMT tandem mass tagging
  • FIG. 11 shows an immunoblot against c-Myc and Max (c-Myc: 9E10, Santa Cruz Biotechnology; Max: H-2, Santa Cruz Biotechnology). Max was immunoprecipitated and c-Myc was co-immunoprecipitated using the ⁇ -Max antibody both in the presence and absence of KI-MS2-008, but not with control antibody.
  • P493-6 cells were washed twice with cold PBS and resuspended in modified RIPA buffer (200 mM NaCl, 50 mM Tris, 1% NP-40, 0.1 g/100 mL sodium deoxycholate, protease inhibitor cocktail, phosphatase inhibitor, 0.4 ⁇ L benzonase per 10 mL buffer, pH 7.5) at a density of about 50 million cells per mL of modified RIPA buffer. Cell resuspensions were vortexed briefly and left on ice for 20 min. The mixture was spun down at 14,000 g for 10 min at 4° C. The supernatant following centrifugation was the whole cell lysate.
  • modified RIPA buffer 200 mM NaCl, 50 mM Tris, 1% NP-40, 0.1 g/100 mL sodium deoxycholate, protease inhibitor cocktail, phosphatase inhibitor, 0.4 ⁇ L benzonase per 10 mL buffer, pH 7.5
  • Protein concentrations were estimated via Bradford assay and 4 mg of total protein was incubated with 2 ⁇ L DMSO or 10 mM KI-MS2-008 for 30 min before adding ⁇ -Max antibody or control antibody. After an overnight incubation at 4° C., 50 ⁇ L of washed Dynabeads® Protein G for Immunoprecipitation (ThermoFisher Scientific) were added and allowed to incubate for 1 hour at 4° C. Beads were collected and washed three times with wash buffer. For one replicate of beads, 30 ⁇ L of 2 ⁇ Laemmli sample buffer with 2-mercaptoethanol was added and boiled at 90° C. for 5 min to elute.
  • FIG. 12 shows interactomics data of ⁇ -Max Ab ( ⁇ KI-MS2-008)/control IgG in a scatterplot.
  • each dot represents a protein. Proteins that appear in the upper right quadrant are enriched in the first condition, while those that appear in the bottom left quadrant are enriched in the second condition.
  • Some known interactors of Max are shown enriched in the Max Co—IP.
  • FIG. 13 shows interactomics data of ⁇ -Max Ab (+KI-MS2-008)/control IgG in a scatterplot. In the presence of KI-MS2-008, similar proteins are enriched when ⁇ -Max antibody is used compared to the control antibody.
  • FIG. 14 shows the impact of KI-MS2-008 on Max interactome in a scatterplot.
  • FIGS. 15A to 15C show KI-MS2-008 Max Homodimer Stabilization Hypothesis for MoA.
  • FIG. 15A shows electrophoretic mobility shift assays (EMSAs), which demonstrate that KI-MS2-008 does not disrupt the c-Myc/Max heterodimer.
  • FIG. 15B shows an EMSA experiment with recombinant Max, which revealed a dose-dependent increase of Max homodimer binding to DNA. This leads to a hypothesize that KI-MS2-008 stabilizes the Max homodimer.
  • FIG. 15C shows further evidence of this by quantifying the relative populations of the Max monomer vs. Max homodimer by fPLC. Addition of KI-MS2-008 induced dimerization of the Max homodimer by 9.9%.
  • FIGS. 16A to 16B show that KI-MS2-008 decreases Myc protein levels ( FIG. 16A ), which can be recovered by Proteasome inhibition ( FIG. 16B ).
  • FIG. 17 shows data for MS2 degronimids first-generation molecules.
  • FIG. 18 shows qPCR data, which indicates that KI-MS2-008 decreases Myc transcript levels.
  • FIG. 19 shows that KI-MS2-008 perturbs transcriptional programs.
  • RNA-seq shows a strong clustering of cell lines and time points with decent clustering of conditions.
  • P493-6 shows relatively sensitive engineered cell line in viability assay. 10 ⁇ M treatment clustered closely with doxycycline treatment, especially at the 8 hour time point.
  • P3HR1 shows relatively insensitive (IC50 51.15 ⁇ M) non-engineered cell line in viability assay. Minimal perturbations to the transcriptome.
  • ST-486 relatively sensitive (IC50 18.71 ⁇ M) non-engineered cell line in viability assay. Clear perturbations to transcriptome at 45 min.
  • FIGS. 20A to 20C show transplanted Luc-labeled cells from MYC-driven lymphoma model into immune-compromised NSG mice.
  • FIG. 20B shows IV administration of 20 ⁇ M in saline+0.1% DMSO, 150 ⁇ L daily dose.
  • FIG. 20C shows IP administration of 10 mg/mL in corn oil, 100 ⁇ L IP, dosed every other day (d2-16); pre-treatment of 4188-Luc cells with 20 ⁇ M in PBS+0.1% DMSO for 24 hours.
  • the data demonstrates that KI-MS2-008 impacts tumor volume in MYC-driven T-ALL model.
  • FIG. 21 shows the results of a LC/MS detection method for MS2-008. The compound peak was detected at ⁇ 9 minutes.
  • FIG. 22 shows the results of a serial dilution-lowest detection limit test.
  • the data demonstrates that MS2-008 is detectable in processed plasma.
  • n 3 mice for each group. Paired t-test between control plasma and other sample sets: *p ⁇ 0.001.
  • FIG. 23 shows LC/MS analysis for compound IV and oral administration comparison.
  • the data indicates that there is a demonstrable level of compound with IV and no significant change in oral saline or cyclodextrin as compared to control plasma.
  • n 3 animals for each group; paired t-test between control plasma and other sample sets: *p ⁇ 0.001.
  • FIG. 26A shows a graph, which indicates that plasma levels of MS2-008 increase slightly following repeated oral dosing.
  • a positive control of plasma collected at 30 minutes of 0.731 mg/kg (200 mM) dosed mice was used. n 5 per group. The inset chart shows data without the positive control sample.
  • FIG. 26B shows pharmacodynamics results following oral delivery of 200 ⁇ M of compound MS2-008 in cyclodextrin.
  • Compound MS2-008 was administered PO at 150 ul of 200 ⁇ M MS2-008 in 20% cyclodextrin+1.4% DMSO, where blood samples were collected from three animals for vehicle control, 30 min, 1, 2, 4, 6 and 24 hours post compound administration.
  • FIG. 27A shows the MAX homodimer induction effect without compound KI-MS2-008 treatment.
  • FIG. 27B shows the MAX homodimer induction effect with 10 ⁇ M compound KI-MS2-008 treatment.
  • Recombinant human Max protein (ab95309) was dialyzed in 20 mM Tris three times to stabilize the chemical potential of the protein. Two samples were prepared for the experiment. Max protein (0.25 mg/mL) and Max protein pre-incubated one hour with 10 ⁇ M MS2-008 were added to the analytical ultracentrifugation (AUC) assembly cells. The assembly cells were positioned into a Beckman XL-I Analytical Ultracentrifuge and centrifuged at 42,000 rpm at 20° C. A sedimentation velocity experiment was started scanning A 280 every ⁇ 1.2 minutes for 18 hours.
  • Untreated Max protein has sedimentation coefficients (c(s)) of 1.574 and 2.593 signifying the monomer and homodimer, respectively, at a 1:6 ratio.
  • Pre-incubating the protein with 10 ⁇ M MS2-008 shifted the distribution to predominantly the Max homodimer at a c(s) of 2.345 with a slight shouldering towards 1.5.
  • the present disclosure provides, in one aspect, compounds of Formula (I′), Formula (I), Formula (II), Formula (II-A), Formula (III), Formula (IV), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof.
  • the compounds described herein may be binders of MAX and/or modulators (e.g., inhibitors or activators) of Myc (e.g., c-Myc, L-Myc, and/or N-Myc), Mad, or Mxi1. Therefore, the compounds are useful in modulating transcription and in the treatment and/or prevention of a variety of diseases and conditions, for example, proliferative diseases such as cancer.
  • pharmaceutical compositions, kits, methods, and uses including a compound described herein.
  • a compound described herein may be MAX binders and/or modulators of Myc (e.g., inhibitors of Myc, Mad, or Mxi1), Mad, or Mxi1.
  • a compound described herein is a compound of Formula (I′), Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.
  • a compound described herein is a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.
  • a compound described herein is a compound of Formula (II-A), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.
  • a compound described herein is a compound of Formula (III), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.
  • a compound described herein is a compound of Formula (IV), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.
  • the compound of Formula (I′) is of the formula:
  • R 1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or nitrogen protecting group;
  • R 2 is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
  • R 4 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
  • R A1 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR, —N(R b ) 2 , —SR, —CN, or —SCN;
  • R A2 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR, —N(R b ) 2 , —SR, —CN, —SCN, —NO 2 , or optionally two instances of R A2 are taken together with the phenyl in Formula (I′) to form substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
  • a 0, 1, 2, 3, or 4;
  • b 0, 1, or 2;
  • z1 and z2 indicate where two instances of R A2 are optionally taken together to form substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl fused with the phenyl moiety in Formula (I′); and
  • R is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, oxygen protecting group, or sulfur protecting group; and
  • each instance of R b is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or nitrogen protecting group, or optionally two R b are taken together to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl.
  • the compound of Formula (I′) is of Formula (I).
  • the compound is of Formula (I):
  • x is 1, 2, 3, 4, or 5;
  • R 1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or nitrogen protecting group;
  • R 2 is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
  • each instance of R 3 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR, —N(R b ) 2 , —SR, —CN, or —SCN;
  • R A is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR, —N(R b ) 2 , —SR, —CN, or —SCN;
  • R A1 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR, —N(R b ) 2 , —SR, —CN, or —SCN;
  • a 0, 1, 2, 3, or 4;
  • b is 0 1, or 2;
  • R is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, oxygen protecting group, or sulfur protecting group; and
  • each instance of R b is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, nitrogen protecting group, or optionally two R b are taken together to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl.
  • Formulae (I′) and (I) include substituent R 1 .
  • R 1 is hydrogen.
  • R 1 is substituted or unsubstituted acyl.
  • R 1 is —C( ⁇ O)R′, wherein R′ is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • R′ is substituted or unsubstituted C 1-6 alkyl. In certain embodiments, R′ is substituted methyl (e.g., —CF 3 or —CH 2 OH). In certain embodiments, R′ is methyl. In certain embodiments, R is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl). In certain embodiments, R′ is substituted phenyl. In certain embodiments, R′ is unsubstituted phenyl. In certain embodiments, R′ is of the formula:
  • R 1 is substituted or unsubstituted C 1-6 alkyl. In certain embodiments, R 1 is unsubstituted C 1-6 alkyl. In certain embodiments, R 1 is substituted C 1-6 alkyl. In certain embodiments, R 1 is of the formula: —(CH 2 ) n R a , wherein: n is 1, 2, 3, 4, 5, or 6; R a is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR a2 , —C( ⁇ O)OR a2 , —C( ⁇ O)N(R aa ) 2 , —N(R aa ) 2 ,
  • n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. In certain embodiments, n is 4. In certain embodiments, n is 5. In certain embodiments, n is 6. In certain embodiments, R a is substituted or unsubstituted C 1-6 alkyl. In certain embodiments, R a is substituted or unsubstituted alkenyl (e.g., substituted or unsubstituted C 2-6 alkenyl). In certain embodiments, R a is substituted or unsubstituted alkynyl (e.g., substituted or unsubstituted C 2-6 alkynyl).
  • R a is substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • R a is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • R a is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl). In certain embodiments, R a is benzyl. In certain embodiments, R a is substituted or unsubstituted phenyl. In certain embodiments, R a is substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur.
  • R a is —OR a2 (e.g., —OH, —O(substituted or unsubstituted C 1-6 alkyl) (e.g., —OMe, —OCF 3 , —OEt, —OPr, —OBu, or —OBn), or —O(substituted or unsubstituted phenyl) (e.g., —OPh)).
  • R a2 is hydrogen.
  • R a2 is substituted or unsubstituted C 1-6 alkyl.
  • R a2 is substituted or unsubstituted alkenyl (e.g., substituted or unsubstituted C 2-6 alkenyl). In certain embodiments, R a2 is substituted or unsubstituted alkynyl (e.g., substituted or unsubstituted C 2-6 alkynyl). In certain embodiments, R a2 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl). In certain embodiments, R a2 is substituted or unsubstituted benzyl. In certain embodiments, R a2 is oxygen protecting group.
  • R a2 is sulfur protecting group. In certain embodiments, R a is —C( ⁇ O)OR a2 . In certain embodiments, R a is —SO 2 R a2 . In certain embodiments, R 1 is of the formula:
  • R 1 is of the formula:
  • R a is —C( ⁇ O)N(R aa ) 2 .
  • n is 1, and R a is —C( ⁇ O)N(R aa ) 2 .
  • R 1 is of the formula:
  • R 1 is of the formula:
  • R a3 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • R 1 is of the formula:
  • R 1 is of the formula:
  • R a3 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • R 1 is of the formula:
  • R 1 is of the formula:
  • L 1 is a linker of formula:
  • R a3 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • L 1 is a linker of formula:
  • R a3 is hydrogen. In certain embodiments, R a3 is substituted or unsubstituted C 1-6 alkyl. In certain embodiments, R a3 is of the formula: —(CH 2 ) c R a4 , wherein: c is 1, 2, 3, 4, or 5; and R a4 is substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In certain embodiments, c is 1. In certain embodiments, c is 2. In certain embodiments, c is 3. In certain embodiments, c is 4. In certain embodiments, c is 5.
  • R a3 is substituted or unsubstituted alkenyl (e.g., substituted or unsubstituted C 2-6 alkenyl).
  • R a is substituted or unsubstituted alkynyl (e.g., substituted or unsubstituted C 2-6 alkynyl).
  • R a3 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • R a3 is a substituted or unsubstituted bicyclic heterocycle.
  • R a3 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • R a4 is substituted or unsubstituted heteroaryl.
  • R a4 is substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur.
  • R a4 is substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur.
  • R a3 is of the formula:
  • R a3 is of the formula:
  • R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • R 1 is H
  • R 1 is of the formula:
  • R a3 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and n is 0, 1, 2, 3, 4, 5, or 6. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. In certain embodiments, n is 4. In certain embodiments, n is 5. In certain embodiments, n is 6. In certain embodiments, R 1 is of the formula:
  • R 1 is of the formula:
  • v is 0 or 1; and R a5 is substituted or unsubstituted alkyl. In certain embodiments, v is 0. In certain embodiments, v is 1. In certain embodiments, R a5 is substituted or unsubstituted C 1-6 alkyl (e.g., methyl, ethyl, or propyl). In certain embodiments, R 1 is of the formula:
  • R 1 is substituted or unsubstituted alkenyl (e.g., substituted or unsubstituted C 2-6 alkenyl). In certain embodiments, R 1 is of the formula:
  • R 1 is substituted or unsubstituted alkynyl (e.g., substituted or unsubstituted C 2-6 alkynyl).
  • R 1 is substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • R 1 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • R 1 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • R 1 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • heteroaryl e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur
  • R 1 is a nitrogen protecting group (e.g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)).
  • nitrogen protecting group e.g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)).
  • Formulae (I′) and (I) also include substituent R 2 .
  • R 2 is hydrogen.
  • R 2 is halogen (e.g., F, Cl, Br, or I).
  • R 2 is substituted or unsubstituted C 1-6 alkyl.
  • R 2 is of the formula: —CH 2 (R 2b ), wherein: R 2b is: 5 to 8-membered substituted or unsubstituted cycloalkyl, 5 to 10-membered substituted or unsubstituted heterocyclyl, 6 to 14-membered substituted or unsubstituted aryl, or 5 to 10-membered substituted or unsubstituted heteroaryl.
  • R 2b is 5 to 8-membered substituted or unsubstituted cycloalkyl (e.g., cyclohexyl).
  • R 2b is 5 to 10-membered substituted or unsubstituted heterocyclyl.
  • R 2b is substituted or unsubstituted oxetane, substituted or unsubstituted tetrahydropyran, or substituted or unsubstituted morpholine.
  • R 2b is 6 to 14-membered substituted or unsubstituted aryl (e.g., substituted or unsubstituted napthyl).
  • R 2b is 5 to 10-membered substituted or unsubstituted heteroaryl.
  • R 2b is substituted or unsubstituted imidazole, substituted or unsubstituted triazole, substituted or unsubstituted tetrazole, substituted or unsubstituted oxazole, substituted or unsubstituted furan, substituted or unsubstituted thiophene, substituted or unsubstituted thiozole, substituted or unsubstituted oxadiazole, substituted or unsubstituted pyridyl, or substituted or unsubstituted pyrimidine.
  • R 2 is of the formula:
  • R 2 is of the formula:
  • R 2 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • R 2 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • R 2 is substituted benzyl.
  • R 2 is unsubstituted benzyl.
  • R 2 is of the formula:
  • u is 1, 2, 3, 4, or 5; and each instance of R 2a is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR, —N(R b ) 2 , —NO 2 , —SR, or —CN.
  • u is 1.
  • u is 2. In certain embodiments, u is 3. In certain embodiments, u is 4. In certain embodiments, u is 5. In certain embodiments, at least one instance of R 2a is hydrogen. In certain embodiments, at least one instance of R 2a is halogen (e.g., Cl or F). In certain embodiments, at least one instance of R 2a is substituted or unsubstituted acyl (e.g., —C( ⁇ O)Me or —C( ⁇ O)ONHS). In certain embodiments, at least one instance of R 2a is substituted or unsubstituted alkyl (e.g., methyl, ethyl, isopropyl, or butyl).
  • At least one instance of R 2a is —CF 3 . In certain embodiments, at least one instance of R 2a is isopropyl. In certain embodiments, at least one instance of R 2a is substituted or unsubstituted alkenyl. In certain embodiments, at least one instance of R 2a is substituted or unsubstituted alkynyl. In certain embodiments, at least one instance of R 2a is substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • carbocyclyl e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system.
  • At least one instance of R 2a is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur). In certain embodiments, at least one instance of R 2a is
  • At least one instance of R 2a is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • at least one instance of R 2a is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • At least one instance of R 2a is —OR (e.g., —OH or —OMe). In certain embodiments, at least one instance of R 2a is —N(R b ) 2 (e.g., —NMe 2 ). In certain embodiments, at least one instance of R 2a is —NO 2 . In certain embodiments, at least one instance of R 2a is —SR. In certain embodiments, at least one instance of R 2a is —CN.
  • R 2 is substituted phenyl. In certain embodiments, R 2 is unsubstituted phenyl. In certain embodiments, R 2 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • heteroaryl e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroary
  • Formula (I) also includes one or more instances of substituent R 3 .
  • x is 1. In certain embodiments, x is 2. In certain embodiments, x is 3. In certain embodiments, x is 4. In certain embodiments, x is 5. In certain embodiments, at least one instance of R 3 is hydrogen. In certain embodiments, at least one instance of R 3 is halogen (e.g., F, Cl, Br, or I). In certain embodiments, at least one instance of R 3 is F. In certain embodiments, at least one instance of R 3 is Cl. In certain embodiments, at least one instance of R 3 is substituted or unsubstituted acyl.
  • halogen e.g., F, Cl, Br, or I
  • At least one instance of R 3 is substituted or unsubstituted C 1-6 alkyl. In certain embodiments, at least one instance of R 3 is Me. In certain embodiments, at least one instance of R 3 is —CF 3 . In certain embodiments, at least one instance of R 3 is substituted or unsubstituted alkenyl (e.g., substituted or unsubstituted C 2-6 alkenyl). In certain embodiments, at least one instance of R 3 is substituted or unsubstituted alkynyl (e.g., substituted or unsubstituted C 2-6 alkynyl).
  • At least one instance of R 3 is substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • at least one instance of R 3 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • at least one instance of R 3 is of the formula:
  • At least one instance of R 3 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • at least one instance of R 3 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • At least one instance of R 3 is —OR (e.g., —OH, —O(substituted or unsubstituted C 1-6 alkyl) (e.g., —OMe, —OCF 3 , —OEt, —OPr, —OBu, or —OBn), or —O(substituted or unsubstituted phenyl) (e.g., —OPh)).
  • at least one instance of R 3 is —OH.
  • At least one instance of R 3 is of the formula:
  • R d is independently substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • R d is substituted or unsubstituted C 1-6 alkyl.
  • R d is of the formula:
  • R 3 is of the formula: —O(CH 2 ) e OR c1 , wherein e is independently 1, 2, 3, or 4; and R c1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • e is 1.
  • e is 2.
  • e is 3.
  • e is 4.
  • R c1 is hydrogen.
  • R c1 is substituted or unsubstituted C 1-6 alkyl.
  • R c1 is acyl (e.g., acetyl).
  • at least one instance of R 3 is:
  • R c1 is carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • R c1 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • R c1 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • R c1 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • At least one instance of R 3 is —N(R b ) 2 , wherein each instance of R b is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, nitrogen protecting group, or optionally two R b are taken together to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl.
  • At least one instance of R 3 is —NH 2 . In certain embodiments, at least one instance of R 3 is —SR (e.g., —SMe). In certain embodiments, at least one instance of R 3 is —CN. In certain embodiments, at least one instance of R 3 is —SCN.
  • Formula (I) also includes zero or more instances of substituent R A .
  • at least one instance of R A is hydrogen.
  • at least one instance of R A is halogen (e.g., F, Cl, Br, or I).
  • at least one instance of R A is F.
  • at least one instance of R A is Cl.
  • at least one instance of R A is substituted or unsubstituted acyl.
  • at least one instance of R A is substituted or unsubstituted C 1-6 alkyl.
  • At least one instance of R A is substituted or unsubstituted alkenyl (e.g., substituted or unsubstituted C 2-6 alkenyl). In certain embodiments, at least one instance of R A is substituted or unsubstituted alkynyl (e.g., substituted or unsubstituted C 2-6 alkynyl). In certain embodiments, at least one instance of R A is substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • At least one instance of R A is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • at least one instance of R A is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • At least one instance of R A is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • heteroaryl e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur
  • substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or
  • At least one instance of R A is —OR (e.g., —OH, —O(substituted or unsubstituted C 1-6 alkyl) (e.g., —OMe, —OCF 3 , —OEt, —OPr, —OBu, or —OBn), or —O(substituted or unsubstituted phenyl) (e.g., —OPh)).
  • at least one instance of R A is —OH.
  • At least one instance of R A is —N(R b ) 2 (e.g., —NH 2 , —NH(substituted or unsubstituted C 1-6 alkyl) (e.g., —NHMe), or —NMe 2 ). In certain embodiments, at least one instance of R A is —NH 2 .
  • At least one instance of R A is —SR (e.g., —SH, —S(substituted or unsubstituted C 1-6 alkyl) (e.g., —SMe, —SEt, —SPr, —SBu, or —SBn), or —S(substituted or unsubstituted phenyl) (e.g., —SPh)).
  • at least one instance of R A is —CN.
  • at least one instance of R A is —SCN.
  • Formula (I′) also includes substituent R 4 .
  • R 4 is hydrogen.
  • R 4 is substituted or unsubstituted alkyl (e.g., substituted or unsubstituted C 1-6 alkyl).
  • R 4 is substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • R 4 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • R 4 is methyl.
  • R 4 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • R 4 is substituted or unsubstituted phenyl.
  • R 4 is of the formula:
  • R 3 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR, —N(R b ) 2 , —SR, —CN, or —SCN.
  • R 4 is
  • R 4 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • R 4 is substituted or unsubstituted 5 membered heteroaryl.
  • R 4 is substituted or unsubstituted 6-membered heteroaryl.
  • R 4 is of the formula:
  • R 3 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR, —N(R b ) 2 , —SR, —CN, or —SCN.
  • R 4 is of the formula:
  • R 4 is —OR 4a , wherein R 4a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 4 is
  • the compound of Formula (I′) is of the formula:
  • the compound of Formula (I′) is of the formula:
  • the compound of Formula (I) is of the formula:
  • a is 0. In certain embodiments, a is 1. In certain embodiments, a is 2. In certain embodiments, a is 3. In certain embodiments, a is 4.
  • Formulae (I′) and (I) include zero or more instances of substituent R A1 .
  • at least one instance of R A1 is hydrogen.
  • at least one instance of R A1 is halogen (e.g., F, Cl, Br, or I).
  • at least one instance of R A1 is substituted or unsubstituted acyl.
  • at least one instance of R A1 is substituted or unsubstituted C 1-6 alkyl.
  • at least one instance of R A1 is substituted or unsubstituted alkenyl (e.g., substituted or unsubstituted C 2-6 alkenyl).
  • At least one instance of R A1 is substituted or unsubstituted alkynyl (e.g., substituted or unsubstituted C 2-6 alkynyl). In certain embodiments, at least one instance of R A1 is substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • At least one instance of R A1 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • at least one instance of R A1 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • At least one instance of R A1 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • heteroaryl e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur
  • substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen,
  • At least one instance of R A1 is —OR (e.g., —OH, —O(substituted or unsubstituted C 1-6 alkyl) (e.g., —OMe, —OCF 3 , —OEt, —OPr, —OBu, or —OBn), or —O(substituted or unsubstituted phenyl) (e.g., —OPh)).
  • OR e.g., —OH, —O(substituted or unsubstituted C 1-6 alkyl) (e.g., —OMe, —OCF 3 , —OEt, —OPr, —OBu, or —OBn), or —O(substituted or unsubstituted phenyl) (e.g., —OPh)).
  • R A1 is —N(R b ) 2 (e.g., —NH 2 , —NH(substituted or unsubstituted C 1-6 alkyl) (e.g., —NHMe)), or —NMe 2 ).
  • at least one instance of R A1 is —SR (e.g., —SH, —S(substituted or unsubstituted C 1-6 alkyl) (e.g., —SMe, —SEt, —SPr, —SBu, or —SBn), or —S(substituted or unsubstituted phenyl) (e.g., —SPh)).
  • at least one instance of R A1 is —CN.
  • at least one instance of R A1 is —SCN.
  • b is 0. In certain embodiments, b is 1. In certain embodiments, b is 2. In certain embodiments, one instance of R A1 is hydrogen, and the other instance is a non-hydrogen substituent. In certain embodiments, both instances of R A1 are hydrogen. In certain embodiments, both instances of R A1 are non-hydrogen substituents.
  • Formula (I′) includes zero or more instances of substituent R A2 .
  • at least one instance of R A2 is hydrogen.
  • at least one instance of R A2 is halogen (e.g., F, Cl, Br, or I).
  • at least one instance of R A2 is substituted or unsubstituted acyl.
  • at least one instance of R A2 is substituted or unsubstituted alkyl (e.g., substituted or unsubstituted C 1-6 alkyl).
  • at least one instance of R A2 is substituted or unsubstituted alkenyl (e.g., substituted or unsubstituted C 2-6 alkenyl).
  • At least one instance of R A2 is substituted or unsubstituted alkynyl (e.g., substituted or unsubstituted C 2-6 alkynyl). In certain embodiments, at least one instance of R A2 is substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • At least one instance of R A2 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • at least one instance of R A2 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • At least one instance of R A2 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • heteroaryl e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur
  • substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen,
  • At least one instance of R A2 is —OR (e.g., —OH, —O(substituted or unsubstituted C 1-6 alkyl) (e.g., —OMe, —OCF 3 , —OEt, —OPr, —OBu, or —OBn), or —O(substituted or unsubstituted phenyl) (e.g., —OPh)).
  • OR e.g., —OH, —O(substituted or unsubstituted C 1-6 alkyl) (e.g., —OMe, —OCF 3 , —OEt, —OPr, —OBu, or —OBn), or —O(substituted or unsubstituted phenyl) (e.g., —OPh)).
  • At least one instance of R A2 is —N(R b ) 2 (e.g., —NH 2 , —NH(substituted or unsubstituted C 1-6 alkyl) (e.g., —NHMe)), or —NMe 2 ).
  • R A2 is —N(R b ) 2 (e.g., —NH 2 , —NH(substituted or unsubstituted C 1-6 alkyl) (e.g., —NHMe)), or —NMe 2 ).
  • At least one instance of R A2 is —SR (e.g., —SH, —S(substituted or unsubstituted C 1-6 alkyl) (e.g., —SMe, —SEt, —SPr, —SBu, or —SBn), or —S(substituted or unsubstituted phenyl) (e.g., —SPh)).
  • at least one instance of R A2 is —CN.
  • at least one instance of R A2 is —SCN.
  • at least one instance of R A2 is —NO 2 .
  • two instances of R A2 are taken together with the phenyl in Formula (I′) to form substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • Z1 and z2 indicate where two instances of R A2 are optionally taken together to form substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl fused with the phenyl moiety in Formula (I′).
  • one instance of R A2 is hydrogen, and the other instance is a non-hydrogen substituent.
  • both instances of R A2 are hydrogen.
  • both instances of R A2 are non-hydrogen substituents.
  • two instances of R A2 are taken together to form substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl fused with the phenyl moiety in Formula (I′), of the formula:
  • w is 0, 1, 2, 3, or 4; and each instance of R B is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR, —N(R b ) 2 , —NO 2 , —SR, —CN, or —SCN. In certain embodiments, w is 0.
  • w is 1. In certain embodiments, w is 2. In certain embodiments, w is 3. In certain embodiments, w is 4. In certain embodiments, at least one instance of R B is hydrogen. In certain embodiments, at least one instance of R B is hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR, —N(R b ) 2 , —NO 2 , —SR, —CN, or —SCN. In certain embodiments, at least one instance of R B is hydrogen, F, —NO 2 , CN, or —CO 2 H.
  • two instances of R A2 are taken together with the phenyl in Formula (I′) to form a compound of the formula:
  • the compound of Formula (I′) is of the following formula:
  • the compound of Formula (I′) is of the following formula:
  • the compound of Formula (I) is of the following formula:
  • the compound of Formula (I) is of the following formula:
  • the compound of Formulae (I′) or (I) is of the formula:
  • the compound of Formula (I) is of the formula:
  • the compound is of Formula (II):
  • j is 1, 2, 3, 4, or 5;
  • R B1 is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR d1 , —N(R zz ) 2 , —SR d1 , —CN, —SCN, or —SO 2 R d1 ;
  • R B2 is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR d1 , —N(R zz ) 2 , —SR d1 , —CN, —SCN, or —SO 2 R d1 ;
  • R B1 and R B2 are taken together to form ⁇ O, a spiro-linked, substituted or unsubstituted carbocyclyl, or a spiro-linked, substituted or unsubstituted heterocyclyl;
  • R B3 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR d1 , —N(R zz ) 2 , —SR d1 , —CN, —SCN;
  • R d1 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, oxygen protecting group, sulfur protecting group, or —SO 2 R′′; and
  • each instance of R zz is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, nitrogen protecting group, or optionally two R zz are taken together to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl;
  • each instance of R′′ is independently hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted aryl;
  • R B4 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR d1 , —N(R zz ) 2 , —SR d1 , —CN, —SCN;
  • R B3 and R B4 are taken together to form ⁇ O, a spiro-linked, substituted or unsubstituted carbocyclyl, or a spiro-linked, substituted or unsubstituted heterocyclyl;
  • each instance of R B5 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR d1 , —N(R zz ) 2 , —SR d1 , —CN, or —SCN.
  • Formula (II) includes substituent R B1 .
  • R B1 is hydrogen.
  • R B1 is halogen (e.g., F, Cl, Br, or I).
  • R B1 is F.
  • R B1 is Cl.
  • R B1 is substituted or unsubstituted C 1-6 alkyl.
  • R B1 is substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • R B1 is cyclopropyl.
  • R B1 is cyclobutyl.
  • R B1 is cyclopentyl.
  • R B1 is of the formula:
  • R B1 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • R B1 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • R B1 is substituted phenyl.
  • R B1 is unsubstituted phenyl.
  • R B1 is of the formula:
  • R d3 is independently substituted or unsubstituted alkyl, halogen, —OR d4 , —N 3 , —N(R d10 ) 2 , —SR d4 , —CN, —SCN, —SO 2 R d4 , —C( ⁇ O)R d4 , —C( ⁇ O)OR d4 , —C( ⁇ O)N(R d10 ) 2 , or —NO 2 ; and R d4 is independently hydrogen, or substituted or unsubstituted C 1-6 alkyl, oxygen protecting group, or sulfur protecting group; and R d10 is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, or nitrogen protecting group, or optionally two R d10 are taken together to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl.
  • k is 0. In certain embodiments, k is 1. In certain embodiments, k is 2. In certain embodiments, k is 3. In certain embodiments, k is 4. In certain embodiments, k is 5. In certain embodiments, R d3 is substituted or unsubstituted C 1-6 alkyl. In certain embodiments, R d3 is:
  • R d3 is halogen (e.g., F, Cl, Br, or I).
  • R d3 is —OR d4 (e.g., —OH, —O(substituted or unsubstituted C 1-6 alkyl) (e.g., —OMe, —OCF 3 , —OEt, —OPr, —OBu, or —OBn), or —O(substituted or unsubstituted phenyl) (e.g., —OPh)).
  • R d4 is substituted or unsubstituted C 1-6 alkyl.
  • R d4 is substituted methyl.
  • R d4 is unsubstituted methyl.
  • R d3 is —OMe.
  • R d3 is —N 3 .
  • R d3 is —N(R d10 ) 2 (e.g., —NH 2 , —NH(substituted or unsubstituted C 1-6 alkyl) (e.g., —NHMe), or —NMe 2 ).
  • R d3 is —SR d4 (e.g., —SH, —S(substituted or unsubstituted C 1-6 alkyl) (e.g., —SMe, —SEt, —SPr, —SBu, or —SBn), or —S(substituted or unsubstituted phenyl) (e.g., —SPh)).
  • R d3 is —CN.
  • R d3 is —SCN.
  • R d3 is —SO 2 R d4 .
  • R d3 is —SO 2 Me.
  • R d3 is —C( ⁇ O)R d4 . In certain embodiments, R d3 is —C( ⁇ O)OR d4 . In certain embodiments, R d3 is —C( ⁇ O)N(R d1 ) 2 . In certain embodiments, R B1 is of the formula:
  • R B1 is of the formula:
  • R B1 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • R B1 is of the formula:
  • R B1 is thiophenyl. In certain embodiments, R B1 is pyrrole. In certain embodiments, R B1 is —OR d1 , wherein R d1 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, oxygen protecting group, or sulfur protecting group. In certain embodiments, R B1 is —OR d1 (e.g., —OMe).
  • R B1 is —N(R zz ) 2 , wherein each instance of R zz is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, nitrogen protecting group, or optionally two R zz are taken together to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl (e.g., —NMe 2 ).
  • R zz is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyn
  • R B1 is —SR d1 (e.g., —SMe). In certain embodiments, R B1 is —CN. In certain embodiments, R B1 is —SCN. In certain embodiments, R B1 is —SO 2 R′′.
  • Formula (II) also includes substituent R B2 .
  • R B2 is hydrogen.
  • R B2 is halogen (e.g., F, Cl, Br, or I).
  • R B1 is F.
  • R B2 is Cl.
  • R B2 is substituted or unsubstituted C 1-6 alkyl.
  • R B2 is substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • R B2 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • R B2 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • R B2 is substituted phenyl.
  • R B2 is unsubstituted phenyl.
  • R B2 is of the formula:
  • R d3 is independently substituted or unsubstituted alkyl, halogen, —OR d4 , —N 3 , —N(R d10 ) 2 , —SR d4 , —CN, —SCN, —SO 2 R d4 , —C( ⁇ O)R d4 , —C( ⁇ O)OR d4 , —C( ⁇ O)N(R d10 ) 2 , or —NO 2 ; and R d4 is independently hydrogen, or substituted or unsubstituted C 1-6 alkyl, oxygen protecting group, or sulfur protecting group; and R d10 is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, or nitrogen protecting group, or optionally two R d10 are taken together to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl.
  • k is 0. In certain embodiments, k is 1. In certain embodiments, k is 2. In certain embodiments, k is 3. In certain embodiments, k is 4. In certain embodiments, k is 5. In certain embodiments, R d3 is substituted or unsubstituted C 1-6 alkyl. In certain embodiments, R d3 is:
  • R d3 is halogen (e.g., F, Cl, Br, or I). In certain embodiments, R d3 is —N 3 . In certain embodiments, R B2 is of the formula:
  • R d3 is —N(R d10 ) 2 (e.g., —NH 2 ). In certain embodiments, R d3 is —SR d4 . In certain embodiments, R d3 is —CN. In certain embodiments, R d3 is —SCN. In certain embodiments, R d3 is —SO 2 R d4 . In certain embodiments, R d3 is —C( ⁇ O)R d4 . In certain embodiments, R d3 is —C( ⁇ O)OR d4 . In certain embodiments, R d3 is —C( ⁇ O)N(R d10 ) 2 . In certain embodiments, R d3 is —NO 2 .
  • R B2 is —OR d1 (e.g., —OMe). In certain embodiments, R B2 is —N(R zz ) 2 (e.g., —NMe 2 ). In certain embodiments, R B2 is —SR d1 (e.g., —SMe). In certain embodiments, R B2 is —CN. In certain embodiments, R B2 is —SCN. In certain embodiments, R B2 is —SO 2 R d1 .
  • substituents R B1 and R B2 are taken together to form ⁇ O. In certain embodiments, substituents R B1 and R B2 are taken together to form a spiro-linked, substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • substituents R B1 and R B2 are taken together to form spiro-linked, substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • substituents R B1 and R B2 are taken together to form:
  • Formula (II) may include substituent R B3 .
  • R B3 is hydrogen.
  • R B3 is halogen (e.g., F, Cl, Br, or I).
  • R B3 is substituted or unsubstituted acyl.
  • R B3 is of the formula: —C( ⁇ O)OR d1 , wherein R d1 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, oxygen protecting group, sulfur protecting group, or —SO 2 R′′; and each instance of R′′ is independently hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted aryl.
  • R B3 is —C( ⁇ O)OH or —C( ⁇ O)OMe. In certain embodiments, R B3 is —C( ⁇ O)R d1 (e.g., —C( ⁇ O)Me).
  • R B3 is of the formula: —C( ⁇ O)N(R d2 ) 2 ; and each occurrence of R d2 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, nitrogen protecting group, or two instances of R d2 are taken together to form a substituted or unsubstituted, heterocyclic ring. In certain embodiments, at least one instance of R d2 is hydrogen.
  • At least one instance of R d2 is substituted or unsubstituted C 1-6 alkyl.
  • at least one instance of R d2 is of the formula: —(CH 2 ) p OR d5 , or —(CH 2 ) p C( ⁇ O)OR d5 , wherein: p is 1, 2, 3, 4, 5, or 6; and R d5 is independently hydrogen, or substituted or unsubstituted C 1-6 alkyl.
  • p is 1.
  • p is 2.
  • p is 3.
  • at least one instance of R d2 is —(CH 2 ) 2 OH or —(CH 2 )OMe.
  • At least one instance of R d2 is substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system). In certain embodiments, at least one instance of R d2 is substituted or unsubstituted, 3- to 9-membered, monocyclic heterocyclic ring comprising zero, one, or two double bonds in the heterocyclic ring system, wherein one, two, or three atoms of the heterocyclic ring system are independently nitrogen, oxygen, or sulfur.
  • At least one instance of R d2 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl). In certain embodiments, at least one instance of R d2 is substituted phenyl. In certain embodiments, at least one instance of R d2 is unsubstituted phenyl.
  • two instances of R d2 are taken together to form a substituted or unsubstituted, 3- to 9-membered, monocyclic heterocyclic ring comprising zero, one, or two double bonds in the heterocyclic ring system, wherein one, two, or three atoms of the heterocyclic ring system are independently nitrogen, oxygen, or sulfur.
  • two instances of R d2 are taken together to form a ring of formula:
  • R B3 is substituted or unsubstituted C 1-6 alkyl. In certain embodiments, R B3 is of the formula: —CH 2 OR d 1. In certain embodiments, R d1 is hydrogen. In certain embodiments, R d1 is substituted or unsubstituted C 1-6 alkyl. In certain embodiments, R d1 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl). In certain embodiments, R d1 is substituted phenyl. In certain embodiments, R d1 is unsubstituted phenyl. In certain embodiments, R B3 is: —CH 2 OH.
  • R B3 is substituted or unsubstituted alkenyl (e.g., substituted or unsubstituted C 2-6 alkenyl). In certain embodiments, R B3 is substituted or unsubstituted alkynyl (e.g., substituted or unsubstituted C 2-6 alkynyl). In certain embodiments, R B3 is substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • R B3 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • R B3 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • R B3 is substituted benzyl.
  • R B3 is unsubstituted benzyl.
  • R B3 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • R B3 is —OR d1 (e.g., —OMe).
  • R B3 is —N(R zz ) 2 (e.g., —NMe 2 ). In certain embodiments, R B3 is —SR d1 (e.g., —SMe). In certain embodiments, R B3 is —CN. In certain embodiments, R B3 is —SCN.
  • Formula (II) includes substituent R B4 .
  • R B4 is hydrogen.
  • R B4 is halogen (e.g., F, Cl, Br, or I).
  • R B4 is substituted or unsubstituted acyl.
  • R B4 is of the formula: —C( ⁇ O)OR d1 , wherein R d1 is substituted or unsubstituted C 1-6 alkyl.
  • R B4 is —C( ⁇ O)R d1 .
  • R B4 is of the formula: —C( ⁇ O)N(R d2 ) 2 (e.g., —C( ⁇ O)NHMe).
  • R B4 is substituted or unsubstituted C 1-6 alkyl.
  • R B4 is of the formula: —(CH 2 ) m R d1 , —(CH 2 ) m OR d1 , or —C( ⁇ O)OR d1 , wherein m is 1, 2, or 3.
  • m is 1.
  • m is 2.
  • m is 3.
  • R d1 is hydrogen.
  • R d1 is substituted or unsubstituted C 1-6 alkyl.
  • R d1 is substituted or unsubstituted alkenyl (e.g., substituted or unsubstituted C 2-6 alkenyl). In certain embodiments, R d1 is substituted or unsubstituted alkynyl (e.g., substituted or unsubstituted C 2-6 alkynyl). In certain embodiments, R d1 is —SO 2 Ph. In certain embodiments, R B4 is
  • R B4 is substituted or unsubstituted alkenyl (e.g., substituted or unsubstituted C 2-6 alkenyl). In certain embodiments, R B4 is substituted or unsubstituted alkynyl (e.g., substituted or unsubstituted C 2-6 alkynyl). In certain embodiments, R B4 is substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • R B4 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • R B4 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • R B4 is substituted benzyl.
  • R B4 is unsubstituted benzyl.
  • R B4 is substituted phenyl.
  • R B4 is unsubstituted phenyl. In certain embodiments, R B4 is substituted napthyl. In certain embodiments, R B4 is unsubstituted napthyl. In certain embodiments, R B4 is of the formula:
  • R d6 is independently hydrogen, halogen, substituted or unsubstituted alkyl, —N(R d7 ) 2 , —S(R d7 ), or —OR d7 , wherein R d7 is independently hydrogen or substituted or unsubstituted alkyl.
  • R d6 is hydrogen.
  • R d6 is halogen (e.g., F, Cl, Br, or I).
  • R d6 is substituted or unsubstituted C 1-6 alkyl.
  • R d6 is
  • R d6 is isopropyl.
  • R d6 is —N(R d7 ) 2 (e.g., —NH 2 , —NH(substituted or unsubstituted C 1-6 alkyl) (e.g., —NHMe), or —NMe 2 ).
  • R d6 is —S(R d7 ) (e.g., —SH, —S(substituted or unsubstituted C 1-6 alkyl) (e.g., —SMe, —SEt, —SPr, —SBu, or —SBn), or —S(substituted or unsubstituted phenyl) (e.g., —SPh)).
  • S(R d7 ) e.g., —SH, —S(substituted or unsubstituted C 1-6 alkyl) (e.g., —SMe, —SEt, —SPr, —SBu, or —SBn), or —S(substituted or unsubstituted phenyl) (e.g., —SPh)).
  • R d6 is —OR d7 (e.g., —OH, —O(substituted or unsubstituted C 1-6 alkyl) (e.g., —OMe, —OCF 3 , —OEt, —OPr, —OBu, or —OBn), or —O(substituted or unsubstituted phenyl) (e.g., —OPh)).
  • R d7 is substituted or unsubstituted C 1-6 alkyl.
  • R d6 is —OMe.
  • R B4 is of the formula:
  • R B4 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • R B4 is —OR d1 (e.g., —OMe).
  • R B4 is —N(R zz ) 2 (e.g., —NMe 2 ). In certain embodiments, R B4 is —SR d1 (e.g., —SMe). In certain embodiments, R B4 is —CN. In certain embodiments, R B4 is —SCN. In certain embodiments, substituents R B3 and R B4 are taken together to form ⁇ O.
  • substituents R B3 and R B4 are taken together to form a spiro-linked, substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • substituents R B3 and R B4 are taken together to form a spiro-linked, substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • Formula (II) includes one or more instances of substituent R B5 .
  • j is 1. In certain embodiments, j is 2. In certain embodiments, j is 3. In certain embodiments, j is 4. In certain embodiments, j is 5. In certain embodiments, at least one instance of R B5 is hydrogen. In certain embodiments, at least one instance of R B5 is halogen (e.g., F, Cl, Br, or I). In certain embodiments, at least one instance of R B5 is substituted or unsubstituted acyl. In certain embodiments, R B5 is substituted or unsubstituted C 1-6 alkyl.
  • At least one instance of R B5 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • at least one instance of R B5 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • R B5 is —OR (e.g., —OH, —O(substituted or unsubstituted C 1-6 alkyl) (e.g., —OMe, —OCF 3 , —OEt, —OPr, —OBu, or —OBn), or —O(substituted or unsubstituted phenyl) (e.g., —OPh)).
  • OR e.g., —OH, —O(substituted or unsubstituted C 1-6 alkyl) (e.g., —OMe, —OCF 3 , —OEt, —OPr, —OBu, or —OBn), or —O(substituted or unsubstituted phenyl) (e.g., —OPh)).
  • R B5 is of the formula: —O(CH 2 ) f OR d8 , wherein: f is 1, 2, 3, 4, 5, or 6; and R d8 is independently hydrogen or substituted or unsubstituted C 1-6 alkyl.
  • f is 1.
  • f is 2.
  • f is 3.
  • f is 4.
  • f is 5.
  • f is 6.
  • R d8 is substituted or unsubstituted C 1-6 alkyl.
  • at least one instance of R B5 is of the formula:
  • R d9 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • R B5 is of the formula:
  • R d9 is substituted or unsubstituted C 1-6 alkyl. In certain embodiments, R d9 is
  • At least one instance of R B5 is of the formula:
  • R d9 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl). In certain embodiments, R d9 is substituted phenyl. In certain embodiments, R d9 is unsubstituted phenyl. In certain embodiments, R d9 is of the formula:
  • R d9 is substituted or unsubstituted heteroaryl.
  • at least one instance of R B5 is —OR d1 (e.g., —OMe).
  • at least one instance of R B5 is —N(R zz ) 2 (e.g., —NMe 2 ).
  • at least one instance of R B5 is —SR d1 (e.g., —SMe).
  • at least one instance of R B5 is —CN.
  • at least one instance of R B5 is —SCN.
  • the compound of Formula (II) is of the following formula:
  • the compound of Formula (II) is of the formula:
  • the compound of Formula (II) is of the formula:
  • the compound is of Formula (II-A):
  • R B1 is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, —OR d1 , —N(R zz ) 2 , —SR d1 , —CN, —SCN, or —SO 2 R d1 ;
  • R B2 is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, —OR d1 , —N(R zz ) 2 , —SR d1 , —CN, —SCN, or —SO 2 R d1 ;
  • R B1 and R B2 are taken together to form ⁇ O, a spiro-linked, substituted or unsubstituted carbocyclyl, or a spiro-linked, substituted or unsubstituted heterocyclyl;
  • R B3 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR d1 , —N(R zz ) 2 , —SR d1 , —CN, or —SCN;
  • R d1 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, oxygen protecting group, sulfur protecting group, or —SO 2 R′′;
  • each instance of R zz is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, nitrogen protecting group, or optionally two R zz are taken together to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl;
  • each instance of R′′ is independently hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted aryl;
  • R B4 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR d1 , —N(R zz ) 2 , —SR d1 , —CN, —SCN;
  • R B3 and R B4 are taken together to form ⁇ O, a spiro-linked, substituted or unsubstituted carbocyclyl, or a spiro-linked, substituted or unsubstituted heterocyclyl.
  • Formula (II-A) includes substituent R B .
  • R B1 is hydrogen.
  • R B1 is halogen (e.g., F, Cl, Br, or I).
  • R B1 is substituted or unsubstituted C 1-6 alkyl.
  • R B1 is substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • R B1 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • R B1 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • R B1 is substituted phenyl.
  • R B1 is unsubstituted phenyl.
  • R B1 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • R B1 is —OR d1 (e.g., —OMe).
  • R B1 is —N(R zz ) 2 (e.g., —NMe 2 ). In certain embodiments, R B1 is —SR d1 (e.g., —SMe). In certain embodiments, R B1 is —CN. In certain embodiments, R B1 is —SCN. In certain embodiments, R B1 is —SO 2 R d1 .
  • Formula (II-A) may include substituent R B2 .
  • R B2 is hydrogen.
  • R B2 is halogen (e.g., F, Cl, Br, or I).
  • R B2 is substituted or unsubstituted C 1-6 alkyl.
  • R B2 is substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • R B2 s substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • R B2 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • R B2 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • R B2 is —OR d1 (e.g., —OMe).
  • R B2 is —N(R zz ) 2 (e.g., —NMe 2 ). In certain embodiments, R B2 is —SR d1 (e.g., —SMe). In certain embodiments, R B2 is —CN. In certain embodiments, R B2 is —SCN. In certain embodiments, R B2 is —SO 2 R d1 .
  • substituents R B1 and R B2 are taken together to form ⁇ O. In certain embodiments, substituents R B1 and R B2 are taken together to form a spiro-linked, substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • substituents R B1 and R B2 are taken together to form a spiro-linked, substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • substituted or unsubstituted heterocyclyl e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur.
  • Formula (II-A) includes substituent R B3 .
  • R B3 is hydrogen.
  • R B3 is halogen (e.g., F, Cl, Br, or I).
  • R B3 is substituted or unsubstituted acyl.
  • R B3 is —C( ⁇ O)OR d1 .
  • R d1 is substituted or unsubstituted C 1-6 alkyl.
  • R B3 is substituted or unsubstituted C 1-6 alkyl.
  • R B3 is substituted or unsubstituted alkenyl (e.g., substituted or unsubstituted C 2-6 alkenyl). In certain embodiments, R B3 is substituted or unsubstituted alkynyl (e.g., substituted or unsubstituted C 2-6 alkynyl). In certain embodiments, R B3 is substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • R B3 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • R B3 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • R B3 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • heteroaryl e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur
  • R B3 is —OR d1 (e.g., —OH, —O(substituted or unsubstituted C 1-6 alkyl) (e.g., —OMe, —OCF 3 , —OEt, —OPr, —OBu, or —OBn), or —O(substituted or unsubstituted phenyl) (e.g., —OPh)).
  • OR d1 e.g., —OH, —O(substituted or unsubstituted C 1-6 alkyl) (e.g., —OMe, —OCF 3 , —OEt, —OPr, —OBu, or —OBn), or —O(substituted or unsubstituted phenyl) (e.g., —OPh)).
  • R B3 is —N(R zz ) 2 (e.g., —NH 2 , —NH(substituted or unsubstituted C 1-6 alkyl) (e.g., —NHMe), or —NMe 2 ).
  • R B3 is —SR d1 (e.g., —SH, —S(substituted or unsubstituted C 1-6 alkyl) (e.g., —SMe, —SEt, —SPr, —SBu, or —SBn), or —S(substituted or unsubstituted phenyl) (e.g., —SPh)).
  • R B3 is —CN.
  • R B3 is —SCN.
  • Formula (II-A) may include substituent R B4 .
  • R B4 is hydrogen.
  • R B4 is halogen (e.g., F, Cl, Br, or I).
  • R B4 is substituted or unsubstituted acyl.
  • R B4 is substituted or unsubstituted C 1-6 alkyl.
  • R B4 is substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • R B4 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • R B4 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • R B4 is substituted benzyl.
  • R B4 is unsubstituted benzyl.
  • R B4 is of the formula:
  • R d6 is independently hydrogen, halogen, substituted or unsubstituted alkyl, —N(R d7 ) 2 , —S(R d7 ), or —OR d7 , wherein R d7 is independently hydrogen or substituted or unsubstituted alkyl.
  • R B4 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • R d6 is substituted or unsubstituted C 1-6 alkyl.
  • R d6 is —N(R d7 ) 2 (e.g., —NH 2 , —NH(substituted or unsubstituted C 1-6 alkyl) (e.g., —NHMe), or —NMe 2 ).
  • R d6 is —S(R d7 ) (e.g., —SH, —S(substituted or unsubstituted C 1-6 alkyl) (e.g., —SMe, —SEt, —SPr, —SBu, or —SBn), or —S(substituted or unsubstituted phenyl) (e.g., —SPh)).
  • S(R d7 ) e.g., —SH, —S(substituted or unsubstituted C 1-6 alkyl) (e.g., —SMe, —SEt, —SPr, —SBu, or —SBn), or —S(substituted or unsubstituted phenyl) (e.g., —SPh)).
  • R d6 is —OR d7 (e.g., —OH, —O(substituted or unsubstituted C 1-6 alkyl) (e.g., —OMe, —OCF 3 , —OEt, —OPr, —OBu, or —OBn), or —O(substituted or unsubstituted phenyl) (e.g., —OPh)).
  • R B4 is —OR d1 (e.g., —OMe).
  • R B4 is —N(R zz ) 2 (e.g., —NMe 2 ).
  • R B4 is —SR d1 (e.g., —SMe). In certain embodiments, R B4 is —CN. In certain embodiments, R B4 is —SCN. In certain embodiments, R B4 is —SO 2 R d1 .
  • substituents R B3 and R B4 are taken together to form ⁇ O. In certain embodiments, substituents R B3 and R B4 are taken together to form a spiro-linked, substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • substituents R B3 and R B4 are taken together to form a spiro-linked, substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • substituted or unsubstituted heterocyclyl e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur.
  • the compound of Formula (II-A) is of the formula:
  • the compound of Formula (II-A) is of the following formula:
  • the compound is of Formula (III):
  • y is 1, 2, 3, or 4;
  • z is 1, 2, 3, or 4;
  • R D1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or nitrogen protecting group;
  • R D2 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
  • R D3 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
  • R D4 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
  • R D5 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • Formula (III) includes substituent R D1 .
  • R D1 is hydrogen.
  • R D1 is substituted or unsubstituted acyl (e.g., acetyl).
  • R D1 is —C( ⁇ O)R f1 ; and R f1 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • R f1 is hydrogen. In certain embodiments, R f1 is substituted or unsubstituted C 1-6 alkyl. In certain embodiments, R f1 is substituted or unsubstituted methyl. In certain embodiments, R D1 is substituted or unsubstituted C 1-6 alkyl. In certain embodiments, R D1 is
  • R D1 is substituted or unsubstituted alkenyl (e.g., substituted or unsubstituted C 2-6 alkenyl). In certain embodiments, R D1 is substituted or unsubstituted alkynyl (e.g., substituted or unsubstituted C 2-6 alkynyl). In certain embodiments, R D1 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • alkenyl e.g., substituted or unsubstituted C 2-6 alkenyl
  • R D1 is substituted or unsubstituted alkynyl (e.g., substituted or unsubstituted C 2-6 alkynyl).
  • R D1 is substituted or unsubstitute
  • R D1 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • R D1 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • R D1 is a nitrogen protecting group (e.g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)).
  • nitrogen protecting group e.g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)).
  • Formula (III) includes substituent R D2 .
  • R D2 is hydrogen.
  • R D2 is halogen (e.g., F, Cl, Br, or I).
  • R D2 is substituted or unsubstituted acyl.
  • R D2 is substituted or unsubstituted C 1-6 alkyl.
  • R D2 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • R D2 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl). In certain embodiments, R D2 is substituted phenyl. In certain embodiments, R D2 is unsubstituted phenyl.
  • R D2 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • heteroaryl e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur
  • Formula (III) includes substituent R D3 .
  • R D3 is hydrogen.
  • R D3 is halogen (e.g., F, Cl, Br, or I).
  • R D3 is substituted or unsubstituted acyl.
  • R D3 is substituted or unsubstituted C 1-6 alkyl.
  • R D3 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • R D3 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl). In certain embodiments, R D3 is substituted phenyl. In certain embodiments, R D3 is unsubstituted phenyl.
  • R D3 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • heteroaryl e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur
  • Formula (III) includes one or more instances of substituent R D4 .
  • y is 1. In certain embodiments, y is 2. In certain embodiments, y is 3. In certain embodiments, y is 4. In certain embodiments, at least one instance of R D4 is hydrogen. In certain embodiments, at least one instance of R D4 is halogen (e.g., F, Cl, Br, or I). In certain embodiments, at least one instance of R D4 is substituted or unsubstituted acyl. In certain embodiments, at least one instance of R D4 is substituted or unsubstituted C 1-6 alkyl.
  • At least one instance of R D4 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • at least one instance of R D4 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • at least one instance of R D4 is substituted phenyl.
  • at least one instance of R D4 is unsubstituted phenyl.
  • At least one instance of R D4 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • heteroaryl e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur
  • substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen,
  • Formula (III) includes one or more instances of substituent R D5 .
  • z is 1. In certain embodiments, z is 2. In certain embodiments, z is 3. In certain embodiments, z is 4.
  • at least one instance of R D5 is hydrogen. In certain embodiments, at least one instance of R D5 is halogen (e.g., F, Cl, Br, or I). In certain embodiments, at least one instance of R D5 is substituted or unsubstituted acyl. In certain embodiments, at least one instance of R D5 is substituted or unsubstituted C 1-6 alkyl.
  • At least one instance of R D5 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • at least one instance of R D5 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • at least one instance of R D5 is substituted phenyl.
  • at least one instance of R D5 is unsubstituted phenyl.
  • R D5 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • heteroaryl e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur
  • substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur
  • the compound of Formula (III) is of the following formulae:
  • the compound of Formula (III) is of the formula:
  • the compound of Formula (III) is of the formula:
  • the compound is of Formula (IV):
  • g is 1 or 2;
  • h is 1, 2, 3, or 4;
  • R E1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or nitrogen protecting group;
  • R E2 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
  • R E3 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
  • R E is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
  • R E5 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • Formula (IV) includes substituent R E1 .
  • R E1 is hydrogen.
  • R E1 is halogen (e.g., F, Cl, Br, or I).
  • R E1 is substituted or unsubstituted acyl (e.g., acetyl).
  • R E1 is —C( ⁇ O)R g1
  • R g1 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • R E1 is —C( ⁇ O)OR g1 .
  • R g1 is substituted or unsubstituted C 1-6 alkyl.
  • R g1 is substituted or unsubstituted methyl. In certain embodiments, R g1 is substituted or unsubstituted ethyl. In certain embodiments, R E1 is substituted or unsubstituted C 1-6 alkyl. In certain embodiments, R E1 is —CH 2 C( ⁇ O)OR g1 . In certain embodiments, R E1 is of the formula:
  • R E1 is substituted or unsubstituted alkenyl (e.g., substituted or unsubstituted C 2-6 alkenyl). In certain embodiments, R E1 is substituted or unsubstituted alkynyl (e.g., substituted or unsubstituted C 2-6 alkynyl). In certain embodiments, R E1 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • alkenyl e.g., substituted or unsubstituted C 2-6 alkenyl
  • R E1 is substituted or unsubstituted alkynyl (e.g., substituted or unsubstituted C 2-6 alkynyl).
  • R E1 is substituted or unsubstitute
  • R E1 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • R E1 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • R E1 is a nitrogen protecting group (e.g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)).
  • nitrogen protecting group e.g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)).
  • Formula (IV) includes substituent R E2 .
  • R E2 is hydrogen.
  • R E2 is halogen (e.g., F, Cl, Br, or I).
  • R E2 is substituted or unsubstituted acyl (e.g., acetyl).
  • R E2 is substituted or unsubstituted C 1-6 alkyl.
  • R E2 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • R E2 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl). In certain embodiments, R E2 is substituted phenyl. In certain embodiments, R E2 is unsubstituted phenyl.
  • R E2 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • heteroaryl e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur
  • Formula (IV) includes substituent R E3 .
  • R E3 is hydrogen.
  • R E3 is halogen (e.g., F, Cl, Br, or I).
  • R E3 is substituted or unsubstituted acyl (e.g., acetyl).
  • R E3 is substituted or unsubstituted C 1-6 alkyl.
  • R E3 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • R E3 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl). In certain embodiments, R E3 is substituted phenyl. In certain embodiments, R E3 is unsubstituted phenyl.
  • R E3 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • heteroaryl e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur
  • Formula (IV) includes one or more instances of substituent R E4 .
  • g is 1.
  • g is 2.
  • at least one instance of R E4 is hydrogen.
  • at least one instance of R E4 is halogen (e.g., F, Cl, Br, or I).
  • at least one instance of R E4 is substituted or unsubstituted acyl (e.g., acetyl).
  • at least one instance of R E4 is substituted or unsubstituted C 1-6 alkyl.
  • At least one instance of R E4 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • at least one instance of R E4 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • at least one instance of R E4 is substituted phenyl.
  • at least one instance of R E4 is unsubstituted phenyl.
  • At least one instance of R E4 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • heteroaryl e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur
  • substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen,
  • Formula (IV) includes one or more instances of substituent R E5 .
  • h is 1. In certain embodiments, h is 2. In certain embodiments, h is 3. In certain embodiments, h is 4.
  • at least one instance of R E5 is hydrogen. In certain embodiments, at least one instance of R E5 is halogen (e.g., F, Cl, Br, or I). In certain embodiments, at least one instance of R E5 is substituted or unsubstituted acyl (e.g., acetyl). In certain embodiments, at least one instance of R E5 is substituted or unsubstituted C 1-6 alkyl.
  • At least one instance of R E5 is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclic ring, wherein one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur).
  • at least one instance of R E5 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted, 6- to 10-membered aryl).
  • at least one instance of R E5 is substituted phenyl.
  • at least one instance of R E5 is unsubstituted phenyl.
  • R E5 is substituted or unsubstituted heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
  • heteroaryl e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur
  • substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur
  • the compound of Formula (IV) is of the formula:
  • the compound of Formula (IV) is of the formula:
  • the compounds described herein may bind (e.g., reversibly binding or irreversibly binding, through covalent and/or non-covalent interactions) MAX.
  • the compounds described herein may also prevent or reduce the interaction or binding of MAX with another molecule (e.g., peptide or protein).
  • the compounds described herein may be useful in modulating (e.g., inhibiting) the activity of Myc, Mad, or Mxi1 in a subject in need thereof, treating diseases associated with Myc (e.g., diseases associated with aberrant activity (e.g., increased activity) of Myc) in a subject in need thereof, treating diseases in a subject in need thereof (e.g., proliferative diseases), preventing diseases associated with Myc (e.g., diseases associated with aberrant activity (e.g., increased activity) of Myc) in a subject in need thereof, and/or preventing diseases in a subject in need thereof (e.g., proliferative diseases), and/or as research tools (e.g., for studying Myc (e.g., studying the activity of Myc, studying the role of Myc in transcription or gene regulation) in a subject, biological sample, tissue, or cell).
  • diseases associated with Myc e.g., diseases associated with aberrant activity (e.g., increased activity) of Myc
  • the present disclosure also provides pharmaceutical compositions comprising a compound described herein and optionally a pharmaceutically acceptable excipient.
  • the pharmaceutical compositions may be useful in binding MAX, modulating (e.g., inhibiting) the activity of Myc, Mad, or Mxi1 in a subject in need thereof, treating diseases associated with Myc (e.g., diseases associated with aberrant activity (e.g., increased activity) of Myc) in a subject in need thereof, treating diseases in a subject in need thereof (e.g., proliferative diseases), preventing diseases associated with Myc (e.g., diseases associated with aberrant activity (e.g., increased activity) of Myc) in a subject in need thereof, and/or preventing diseases (e.g., proliferative diseases) in a subject in need thereof.
  • compositions described herein may be useful for modulating (e.g., inhibiting) the transcription of genes controlled by Myc (e.g., c-Myc, L-Myc, or N-Myc), Mad, or Mxi1 in a subject in need thereof.
  • Myc e.g., c-Myc, L-Myc, or N-Myc
  • Mad or Mxi1 in a subject in need thereof.
  • the pharmaceutical compositions described herein may also be useful as research tools, e.g., for studying Myc (e.g., studying the role of Myc in transcription or gene regulation) in a subject, biological sample, tissue, or cell.
  • the Myc is c-Myc. In certain embodiments, the Myc is L-Myc or N-Myc. In certain embodiments, the compositions may bind Mad. In certain embodiments, the compositions may bind Mxi1.
  • the subject being treated is an animal.
  • the animal may be of either sex and may be at any stage of development.
  • the subject described herein is a human.
  • the subject is a non-human animal.
  • the subject is a mammal.
  • the subject is a non-human mammal.
  • the subject is a domesticated animal, such as a dog, cat, cow, pig, horse, sheep, or goat.
  • the subject is a companion animal, such as a dog or cat.
  • the subject is a livestock animal, such as a cow, pig, horse, sheep, or goat.
  • the subject is a zoo animal.
  • the subject is a research animal, such as a rodent (e.g., mouse, rat), dog, pig, or non-human primate.
  • the animal is a genetically engineered animal.
  • the animal is a transgenic animal (e.g., transgenic mice and transgenic pigs).
  • the subject is a fish or reptile.
  • the cell contacted with an effective amount of a compound or pharmaceutical composition described herein is in vitro. In certain embodiments, the contacted cell is ex vivo. In certain embodiments, the contacted cell described herein is in vivo.
  • the compound described herein is provided in an effective amount in the pharmaceutical composition.
  • the effective amount is a therapeutically effective amount.
  • the effective amount is a prophylactically effective amount.
  • a therapeutically effective amount is an amount effective for binding MAX.
  • a therapeutically effective amount is an amount effective for modulating (e.g., inhibiting) the activity of Myc.
  • a therapeutically effective amount is an amount effective for treating a disease disease (e.g., proliferative disease).
  • a therapeutically effective amount is an amount effective for modulating (e.g., inhibiting) the activity of Myc, Mad, or Mxi1 and treating a disease (e.g., proliferative disease).
  • a prophylactically effective amount is an amount effective for modulating (e.g., inhibiting) the activity of Myc, Mad, or Mxi1.
  • a prophylactically effective amount is an amount effective for modulating (e.g., inhibiting) the transcription of genes controlled by Myc (e.g., c-Myc, L-Myc, or N-Myc), Mad, or Mxi1 in a subject in need thereof.
  • a prophylactically effective amount is an amount effective for preventing a disease (e.g., proliferative disease). In certain embodiments, a prophylactically effective amount is an amount effective for modulating (e.g., inhibiting) the activity of Myc, Mad, or Mxi1 and preventing a disease (e.g., proliferative disease).
  • the effective amount is an amount effective for modulating (e.g., inhibiting) the activity of Myc by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98%. In certain embodiments, the effective amount is an amount effective for modulating (e.g., inhibiting) the activity of Myc by not more than 10%, not more than 20%, not more than 30%, not more than 40%, not more than 50%, not more than 60%, not more than 70%, not more than 80%, not more than 90%, not more than 95%, or not more than 98%.
  • compositions described herein can be prepared by any method known in the art of pharmacology.
  • preparatory methods include bringing the compound described herein (i.e., the “active ingredient”) into association with a carrier or excipient, and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping, and/or packaging the product into a desired single- or multi-dose unit.
  • compositions can be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses.
  • a “unit dose” is a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient.
  • the amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage, such as one-half or one-third of such a dosage.
  • Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition described herein will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered.
  • the composition may comprise between 0.1% and 100% (w/w) active ingredient.
  • compositions used in the manufacture of provided pharmaceutical compositions include inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and perfuming agents may also be present in the composition.
  • Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, and mixtures thereof.
  • Exemplary granulating and/or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose, and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, and mixtures thereof.
  • crospovidone cross-linked poly(vinyl-pyrrolidone)
  • sodium carboxymethyl starch sodium starch glycolate
  • Exemplary surface active agents and/or emulsifiers include natural emulsifiers (e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g., bentonite (aluminum silicate) and Veegum (magnesium aluminum silicate)), long chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulos
  • Exemplary binding agents include starch (e.g., cornstarch and starch paste), gelatin, sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums (e.g., acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum®), and larch arabogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts, silicic acid, polymethacrylates, waxes, water, alcohol, and/or mixtures
  • Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, antiprotozoan preservatives, alcohol preservatives, acidic preservatives, and other preservatives.
  • the preservative is an antioxidant.
  • the preservative is a chelating agent.
  • antioxidants include alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.
  • Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and salts and hydrates thereof (e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like), citric acid and salts and hydrates thereof (e.g., citric acid monohydrate), fumaric acid and salts and hydrates thereof, malic acid and salts and hydrates thereof, phosphoric acid and salts and hydrates thereof, and tartaric acid and salts and hydrates thereof.
  • EDTA ethylenediaminetetraacetic acid
  • salts and hydrates thereof e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like
  • citric acid and salts and hydrates thereof e.g., citric acid mono
  • antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
  • antifungal preservatives include butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
  • Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.
  • Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.
  • preservatives include tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant® Plus, Phenonip®, methylparaben, Germall® 115, Germaben® II, Neolone®, Kathon®, and Euxyl®.
  • Exemplary buffering agents include citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer
  • Exemplary lubricating agents include magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and mixtures thereof.
  • Exemplary natural oils include almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, camomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury, sea buckt
  • Exemplary synthetic oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and mixtures thereof.
  • Liquid dosage forms for oral and parenteral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art such as, for example, water or other solvents, so
  • the oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • the conjugates described herein are mixed with solubilizing agents such as Cremophor®, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and mixtures thereof.
  • sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation can be a sterile injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that can be employed are water, Ringer's solution, U.S.P., and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or di-glycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • compositions for rectal or vaginal administration are typically suppositories which can be prepared by mixing the conjugates described herein with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol, or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol, or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active ingredient is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or (a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, (c) humectants such as glycerol, (d) disintegrating agents such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, (e) solution retarding agents such as paraffin, (f) absorption accelerators such as quaternary ammonium compounds, (g) wetting agents such as, for example, cetyl alcohol and glycerol mono
  • Solid compositions of a similar type can be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the art of pharmacology. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • encapsulating compositions which can be used include polymeric substances and waxes.
  • Solid compositions of a similar type can be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
  • the active ingredient can be in a micro-encapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings, and other coatings well known in the pharmaceutical formulating art.
  • the active ingredient can be admixed with at least one inert diluent such as sucrose, lactose, or starch.
  • Such dosage forms may comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may comprise buffering agents. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • encapsulating agents which can be used include polymeric substances and waxes.
  • Dosage forms for topical and/or transdermal administration of a compound described herein may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and/or patches.
  • the active ingredient is admixed under sterile conditions with a pharmaceutically acceptable carrier or excipient and/or any needed preservatives and/or buffers as can be required.
  • the present disclosure contemplates the use of transdermal patches, which often have the added advantage of providing controlled delivery of an active ingredient to the body.
  • Such dosage forms can be prepared, for example, by dissolving and/or dispensing the active ingredient in the proper medium.
  • the rate can be controlled by either providing a rate controlling membrane and/or by dispersing the active ingredient in a polymer matrix and/or gel.
  • Suitable devices for use in delivering intradermal pharmaceutical compositions described herein include short needle devices.
  • Intradermal compositions can be administered by devices which limit the effective penetration length of a needle into the skin.
  • conventional syringes can be used in the classical mantoux method of intradermal administration.
  • Jet injection devices which deliver liquid formulations to the dermis via a liquid jet injector and/or via a needle which pierces the stratum corneum and produces a jet which reaches the dermis are suitable.
  • Ballistic powder/particle delivery devices which use compressed gas to accelerate the compound in powder form through the outer layers of the skin to the dermis are suitable.
  • Formulations suitable for topical administration include, but are not limited to, liquid and/or semi-liquid preparations such as liniments, lotions, oil-in-water and/or water-in-oil emulsions such as creams, ointments, and/or pastes, and/or solutions and/or suspensions.
  • Topically administrable formulations may, for example, comprise from about 1% to about 10% (w/w) active ingredient, although the concentration of the active ingredient can be as high as the solubility limit of the active ingredient in the solvent.
  • Formulations for topical administration may further comprise one or more of the additional ingredients described herein.
  • a pharmaceutical composition described herein can be prepared, packaged, and/or sold in a formulation suitable for pulmonary administration via the buccal cavity.
  • a formulation may comprise dry particles which comprise the active ingredient and which have a diameter in the range from about 0.5 to about 7 nanometers, or from about 1 to about 6 nanometers.
  • Such compositions are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant can be directed to disperse the powder and/or using a self-propelling solvent/powder dispensing container such as a device comprising the active ingredient dissolved and/or suspended in a low-boiling propellant in a sealed container.
  • Such powders comprise particles wherein at least 98% of the particles by weight have a diameter greater than 0.5 nanometers and at least 95% of the particles by number have a diameter less than 7 nanometers. Alternatively, at least 95% of the particles by weight have a diameter greater than 1 nanometer and at least 90% of the particles by number have a diameter less than 6 nanometers.
  • Dry powder compositions may include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form.
  • Low boiling propellants generally include liquid propellants having a boiling point of below 65° F. at atmospheric pressure. Generally the propellant may constitute 50 to 99.9% (w/w) of the composition, and the active ingredient may constitute 0.1 to 20% (w/w) of the composition.
  • the propellant may further comprise additional ingredients such as a liquid non-ionic and/or solid anionic surfactant and/or a solid diluent (which may have a particle size of the same order as particles comprising the active ingredient).
  • compositions described herein formulated for pulmonary delivery may provide the active ingredient in the form of droplets of a solution and/or suspension.
  • Such formulations can be prepared, packaged, and/or sold as aqueous and/or dilute alcoholic solutions and/or suspensions, optionally sterile, comprising the active ingredient, and may conveniently be administered using any nebulization and/or atomization device.
  • Such formulations may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, and/or a preservative such as methylhydroxybenzoate.
  • the droplets provided by this route of administration may have an average diameter in the range from about 0.1 to about 200 nanometers.
  • Formulations described herein as being useful for pulmonary delivery are useful for intranasal delivery of a pharmaceutical composition described herein.
  • Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle from about 0.2 to 500 micrometers. Such a formulation is administered by rapid inhalation through the nasal passage from a container of the powder held close to the nares.
  • Formulations for nasal administration may, for example, comprise from about as little as 0.1% (w/w) to as much as 100% (w/w) of the active ingredient, and may comprise one or more of the additional ingredients described herein.
  • a pharmaceutical composition described herein can be prepared, packaged, and/or sold in a formulation for buccal administration.
  • Such formulations may, for example, be in the form of tablets and/or lozenges made using conventional methods, and may contain, for example, 0.1 to 20% (w/w) active ingredient, the balance comprising an orally dissolvable and/or degradable composition and, optionally, one or more of the additional ingredients described herein.
  • formulations for buccal administration may comprise a powder and/or an aerosolized and/or atomized solution and/or suspension comprising the active ingredient.
  • Such powdered, aerosolized, and/or aerosolized formulations when dispersed, may have an average particle and/or droplet size in the range from about 0.1 to about 200 nanometers, and may further comprise one or more of the additional ingredients described herein.
  • a pharmaceutical composition described herein can be prepared, packaged, and/or sold in a formulation for ophthalmic administration.
  • Such formulations may, for example, be in the form of eye drops including, for example, a 0.1-1.0% (w/w) solution and/or suspension of the active ingredient in an aqueous or oily liquid carrier or excipient.
  • Such drops may further comprise buffering agents, salts, and/or one or more other of the additional ingredients described herein.
  • Other opthalmically-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form and/or in a liposomal preparation. Ear drops and/or eye drops are also contemplated as being within the scope of this disclosure.
  • compositions suitable for administration to humans are principally directed to pharmaceutical compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with ordinary experimentation.
  • compositions described herein are typically formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions described herein will be decided by a physician within the scope of sound medical judgment.
  • the specific therapeutically effective dose level for any particular subject or organism will depend upon a variety of factors including the disease being treated and the severity of the disorder; the activity of the specific active ingredient employed; the specific composition employed; the age, body weight, general health, sex, and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific active ingredient employed; the duration of the treatment; drugs used in combination or coincidental with the specific active ingredient employed; and like factors well known in the medical arts.
  • the compounds and compositions provided herein can be administered by any route, including enteral (e.g., oral), parenteral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and/or drops), mucosal, nasal, bucal, sublingual; by intratracheal instillation, bronchial instillation, and/or inhalation; and/or as an oral spray, nasal spray, and/or aerosol.
  • enteral e.g., oral
  • parenteral intravenous, intramuscular, intra-arterial, intramedullary
  • intrathecal subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal
  • topical as by powders, ointments, creams, and/or drops
  • mucosal nasal,
  • Specifically contemplated routes are oral administration, intravenous administration (e.g., systemic intravenous injection), regional administration via blood and/or lymph supply, and/or direct administration to an affected site.
  • intravenous administration e.g., systemic intravenous injection
  • regional administration via blood and/or lymph supply e.g., via blood and/or lymph supply
  • direct administration e.g., direct administration to an affected site.
  • the most appropriate route of administration will depend upon a variety of factors including the nature of the agent (e.g., its stability in the environment of the gastrointestinal tract), and/or the condition of the subject (e.g., whether the subject is able to tolerate oral administration).
  • the compound or pharmaceutical composition described herein is suitable for topical administration to the eye of a subject.
  • any two doses of the multiple doses include different or substantially the same amounts of a compound described herein.
  • the frequency of administering the multiple doses to the subject or applying the multiple doses to the biological sample, tissue, or cell is three doses a day, two doses a day, one dose a day, one dose every other day, one dose every third day, one dose every week, one dose every two weeks, one dose every three weeks, or one dose every four weeks.
  • the frequency of administering the multiple doses to the subject or applying the multiple doses to the biological sample, tissue, or cell is one dose per day.
  • the frequency of administering the multiple doses to the subject or applying the multiple doses to the biological sample, tissue, or cell is two doses per day.
  • the frequency of administering the multiple doses to the subject or applying the multiple doses to the biological sample, tissue, or cell is three doses per day.
  • the duration between the first dose and last dose of the multiple doses is one day, two days, four days, one week, two weeks, three weeks, one month, two months, three months, four months, six months, nine months, one year, two years, three years, four years, five years, seven years, ten years, fifteen years, twenty years, or the lifetime of the subject, tissue, or cell.
  • the duration between the first dose and last dose of the multiple doses is three months, six months, or one year.
  • the duration between the first dose and last dose of the multiple doses is the lifetime of the subject, tissue, or cell.
  • a dose (e.g., a single dose, or any dose of multiple doses) described herein includes independently between 0.1 ⁇ g and 1 ⁇ g, between 0.001 mg and 0.01 mg, between 0.01 mg and 0.1 mg, between 0.1 mg and 1 mg, between 1 mg and 3 mg, between 3 mg and 10 mg, between 10 mg and 30 mg, between 30 mg and 100 mg, between 100 mg and 300 mg, between 300 mg and 1,000 mg, or between 1 g and 10 g, inclusive, of a compound described herein.
  • a dose described herein includes independently between 1 mg and 3 mg, inclusive, of a compound described herein. In certain embodiments, a dose described herein includes independently between 3 mg and 10 mg, inclusive, of a compound described herein. In certain embodiments, a dose described herein includes independently between 10 mg and 30 mg, inclusive, of a compound described herein. In certain embodiments, a dose described herein includes independently between 30 mg and 100 mg, inclusive, of a compound described herein.
  • Dose ranges as described herein provide guidance for the administration of provided pharmaceutical compositions to an adult.
  • the amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult.
  • a compound or composition, as described herein, can be administered in combination with one or more additional pharmaceutical agents (e.g., therapeutically and/or prophylactically active agents).
  • the compounds or compositions can be administered in combination with additional pharmaceutical agents that improve their activity (e.g., activity (e.g., potency and/or efficacy) in treating a disease (e.g., proliferative disease) in a subject in need thereof, in preventing a disease in a subject in need thereof, in binding MAX and/or modulating (e.g., inhibiting) the activity of Myc in a subject, biological sample, tissue, or cell, or to improve bioavailability, improve safety, reduce drug resistance, reduce and/or modify metabolism, inhibit excretion, and/or modify distribution in a subject, biological sample, tissue, or cell.
  • additional pharmaceutical agents that improve their activity (e.g., activity (e.g., potency and/or efficacy) in treating a disease (e.g., proliferative disease) in a subject
  • a pharmaceutical composition described herein including a compound described herein and an additional pharmaceutical agent shows a synergistic effect that is absent in a pharmaceutical composition including one of the compound and the additional pharmaceutical agent, but not both.
  • the compound or composition can be administered concurrently with, prior to, or subsequent to one or more additional pharmaceutical agents, which may be useful as, e.g., combination therapies.
  • Pharmaceutical agents include therapeutically active agents.
  • Pharmaceutical agents also include prophylactically active agents.
  • Pharmaceutical agents include small organic molecules such as drug compounds (e.g., compounds approved for human or veterinary use by the U.S.
  • CFR Code of Federal Regulations
  • peptides proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides or proteins, small molecules linked to proteins, glycoproteins, steroids, nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, vitamins, and cells.
  • Each additional pharmaceutical agent may be administered at a dose and/or on a time schedule determined for that pharmaceutical agent.
  • the additional pharmaceutical agents may also be administered together with each other and/or with the compound or composition described herein in a single dose or administered separately in different doses.
  • the particular combination to employ in a regimen will take into account compatibility of the compound described herein with the additional pharmaceutical agent(s) and/or the desired therapeutic and/or prophylactic effect to be achieved.
  • the additional pharmaceutical agent(s) in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.
  • the additional pharmaceutical agents include, but are not limited to, anti-proliferative agents, anti-cancer agents, anti-angiogenesis agents, anti-inflammatory agents, immunosuppressants, anti-bacterial agents, anti-viral agents, cardiovascular agents, cholesterol-lowering agents, anti-diabetic agents, anti-allergic agents, contraceptive agents, pain-relieving agents, and combinations thereof.
  • the additional pharmaceutical agent is an anti-proliferative agent (e.g., anti-cancer agent).
  • the additional pharmaceutical agent is ABITREXATE (methotrexate), ADE, Adriamycin RDF (doxorubicin hydrochloride), Ambochlorin (chlorambucil), ARRANON (nelarabine), ARZERRA (ofatumumab), BOSULIF (bosutinib), BUSULFEX (busulfan), CAMPATH (alemtuzumab), CERUBIDINE (daunorubicin hydrochloride), CLAFEN (cyclophosphamide), CLOFAREX (clofarabine), CLOLAR (clofarabine), CVP, CYTOSAR-U (cytarabine), CYTOXAN (cyclophosphamide), ERWINAZE (Asparaginase Erwinia Chrysanthemi), FLUDARA (fludarabine phosphate), FOLEX (methotrexate), FOLEX PFS (methotrexate), GAZYVA
  • the additional pharmaceutical agent is an anti-lymphoma agent.
  • the additional pharmaceutical agent is ABITREXATE (methotrexate), ABVD, ABVE, ABVE-PC, ADCETRIS (brentuximab vedotin), ADRIAMYCIN PFS (doxorubicin hydrochloride), ADRIAMYCIN RDF (doxorubicin hydrochloride), AMBOCHLORIN (chlorambucil), AMBOCLORIN (chlorambucil), ARRANON (nelarabine), BEACOPP, BECENUM (carmustine), BELEODAQ (belinostat), BEXXAR (tositumomab and iodine I 131 tositumomab), BICNU (carmustine), BLENOXANE (bleomycin), CARMUBRIS (carmustine), CHOP, CLAFEN (cyclophosphamide), COPP, COPP-ABV,
  • the additional pharmaceutical agent is REVLIMID (lenalidomide), DACOGEN (decitabine), VIDAZA (azacitidine), CYTOSAR-U (cytarabine), IDAMYCIN (idarubicin), CERUBIDINE (daunorubicin), LEUKERAN (chlorambucil), NEOSAR (cyclophosphamide), FLUDARA (fludarabine), LEUSTATIN (cladribine), or a combination thereof.
  • REVLIMID lacalidomide
  • DACOGEN decitabine
  • VIDAZA azacitidine
  • CYTOSAR-U cytarabine
  • IDAMYCIN idarubicin
  • CERUBIDINE dounorubicin
  • LEUKERAN chlorambucil
  • NEOSAR cyclophosphamide
  • FLUDARA fludarabine
  • LEUSTATIN cladribine
  • the additional pharmaceutical agent is ABITREXATE (methotrexate), ABRAXANE (paclitaxel albumin-stabilized nanoparticle formulation), AC, AC-T, ADE, ADRIAMYCIN PFS (doxorubicin hydrochloride), ADRUCIL (fluorouracil), AFINITOR (everolimus), AFINITOR DISPERZ (everolimus), ALDARA (imiquimod), ALIMTA (pemetrexed disodium), AREDIA (pamidronate disodium), ARIMIDEX (anastrozole), AROMASIN (exemestane), AVASTIN (bevacizumab), BECENUM (carmustine), BEP, BICNU (carmustine), BLENOXANE (bleomycin), CAF, CAMPTOSAR (irinotecan hydrochloride), CAPOX, CAPRELSA (vandetanib), CARBOPLATIN-TAXOL, CARMUBRIS (carmustine), CASODE
  • the additional pharmaceutical agent is a binder or modulator (e.g., inhibitor or activator) of Myc, Mad, or Mxi1.
  • the additional pharmaceutical agent is a protein kinase inhibitor (e.g., tyrosine protein kinase inhibitor).
  • the additional pharmaceutical agent is selected from the group consisting of epigenetic or transcriptional modulators (e.g., DNA methyltransferase inhibitors, histone deacetylase inhibitors (HDAC inhibitors), lysine methyltransferase inhibitors), antimitotic drugs (e.g., taxanes and vinca alkaloids), hormone receptor modulators (e.g., estrogen receptor modulators and androgen receptor modulators), cell signaling pathway inhibitors (e.g., tyrosine protein kinase inhibitors), modulators of protein stability (e.g., proteasome inhibitors), Hsp90 inhibitors, glucocorticoids, all-trans retinoic acids, and other agents that promote differentiation.
  • epigenetic or transcriptional modulators e.g., DNA methyltransferase inhibitors, histone deacetylase inhibitors (HDAC inhibitors), lysine methyltransferase inhibitors
  • antimitotic drugs e.g., taxanes and vinca
  • the compounds described herein or pharmaceutical compositions can be administered in combination with an anti-cancer therapy including, but not limited to, surgery, radiation therapy, transplantation (e.g., stem cell transplantation, bone marrow transplantation), immunotherapy, and chemotherapy.
  • an anti-cancer therapy including, but not limited to, surgery, radiation therapy, transplantation (e.g., stem cell transplantation, bone marrow transplantation), immunotherapy, and chemotherapy.
  • kits e.g., pharmaceutical packs.
  • the kits provided may comprise a pharmaceutical composition or compound described herein and a container (e.g., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container).
  • a container e.g., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container.
  • provided kits may optionally further include a second container comprising a pharmaceutical excipient for dilution or suspension of a pharmaceutical composition or compound described herein.
  • the pharmaceutical composition or compound described herein provided in the first container and the second container are combined to form one unit dosage form.
  • the pharmaceutical composition or compound described herein provided in the first container and the second container are combined to form multiple unit dosages.
  • kits including a first container comprising a compound or pharmaceutical composition as described herein.
  • the compounds in the kits described herein may be useful in binding MAX in a subject in need thereof, modulating (e.g., inhibiting) the activity of Myc, Mad, or Mxi1 in a subject in need thereof, treating diseases associated with Myc (e.g., diseases associated with aberrant activity (e.g., increased activity) of Myc) in a subject in need thereof, treating diseases (e.g., proliferative diseases) in a subject in need thereof, preventing diseases associated with Myc (e.g., diseases associated with aberrant activity (e.g., increased activity) of Myc) in a subject in need thereof, preventing diseases (e.g., proliferative diseases) in a subject in need thereof, and/or regulate transcription of Myc in a subject, biological sample, or tissue.
  • the kits described herein may also be useful as research tools, e.g., for studying Myc (e.g., studying
  • kits described herein further includes instructions for using the compound or pharmaceutical composition included in the kit.
  • a kit described herein may also include information as required by a regulatory agency such as the U.S. Food and Drug Administration (FDA).
  • the information included in the kits is prescribing information.
  • the kits and instructions provide for treating a disease (e.g., proliferative disease) in a subject in need thereof.
  • the kits and instructions provide for preventing a disease (e.g., proliferative disease) in a subject in need thereof.
  • the kits and instructions provide for binding MAX in a subject in need thereof.
  • kits and instructions provide for modulating (e.g., inhibiting) the activity of Myc, Mad, or Mxi1 in a subject, biological sample, tissue, or cell.
  • a kit described herein may include one or more additional pharmaceutical agents described herein as a separate composition.
  • Myc is associated with a wide range of diseases (e.g., proliferative disease).
  • the compounds described herein may bind (e.g., reversibly bind or irreversibly bind) MAX and/or modulating (e.g., inhibiting or increasing) the activity (e.g., aberrant activity, such as increased or decreased activity) of Myc, Mad, or Mxi1.
  • aberrant activity of Myc is increased activity of Myc.
  • Modulation of Myc using the compounds described herein may be an effective approach to treat and/or prevent the disease (e.g., proliferative disease).
  • Compounds described herein that include a small-molecule label may also be useful in identifying the association of Myc with a disease (e.g., proliferative disease).
  • a disease e.g., proliferative disease.
  • the present disclosure thus provides methods of binding MAX in a subject, biological sample, tissue, or cell; methods of modulating (e.g., inhibiting or increasing) the activity of Myc, Mad, or Mxi1 in a subject, biological sample, tissue, or cell; and methods of treating and/or preventing diseases (e.g., proliferative diseases, inflammatory diseases, or autoimmune diseases) in a subject in need thereof.
  • diseases e.g., proliferative diseases, inflammatory diseases, or autoimmune diseases
  • the present disclosure provides methods of modulating (e.g., inhibiting) the transcription of genes controlled by Myc (e.g., c-Myc, L-Myc, or N-Myc) in a subject in need thereof, the methods comprising administering to the subject an effective amount of a compound or pharmaceutical composition described herein.
  • Myc e.g., c-Myc, L-Myc, or N-Myc
  • the present disclosure provides methods of modulating (e.g., inhibiting) the activity of Myc (e.g., c-Myc, L-Myc, or N-Myc), Mad, or Mxi1 in a biological sample, tissue, or cell, the methods comprising contacting the biological sample, tissue, or cell with an effective amount of a compound, or pharmaceutical composition thereof, as described herein.
  • Myc e.g., c-Myc, L-Myc, or N-Myc
  • Mad or Mxi1 in a biological sample, tissue, or cell
  • the activity of Myc in a subject, biological sample, tissue, or cell is inhibited by a compound described herein by at least 1%, at least 3%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, and at least 99.9%.
  • the activity of Myc in a subject, biological sample, tissue, or cell is inhibited by a compound described herein by not more than 1%, not more than 3%, not more than 10%, not more than 20%, not more than 30%, not more than 40%, not more than 50%, not more than 60%, not more than 70%, not more than 80%, or not more than 90%.
  • the activity of Myc in a subject, biological sample, tissue, or cell is selectively inhibited by the compound, pharmaceutical composition, kit, use, or method.
  • the activity of Myc in a subject, biological sample, tissue, or cell is selectively inhibited by the compound, pharmaceutical composition, kit, use, or method, compared to a different transcription factor (e.g., SP1, AP-1, C/EBP, heat shock factor, ATF/CREB, Oct-1, NF-1).
  • a different transcription factor e.g., SP1, AP-1, C/EBP, heat shock factor, ATF/CREB, Oct-1, NF-1).
  • the activity of c-Myc in a subject, biological sample, tissue, or cell is selectively inhibited by the compound, pharmaceutical composition, kit, use, or method, compared to a different Myc (e.g., L-Myc, N-Myc) and/or a different transcription factor (e.g., SP1, AP-1, C/EBP, heat shock factor, ATF/CREB, Oct-1, NF-1).
  • a different Myc e.g., L-Myc, N-Myc
  • a different transcription factor e.g., SP1, AP-1, C/EBP, heat shock factor, ATF/CREB, Oct-1, NF-1
  • the activity of Myc in a subject, biological sample, tissue, or cell is reversibly inhibited by the compound, pharmaceutical composition, kit, use, or method.
  • the activity of Myc in a subject, biological sample, tissue, or cell is irreversibly inhibited by the compound, pharmaceutical composition, kit, use, or method.
  • the compound inhibits the activity of a mutant (e.g., Myc with a point mutantation) form of Myc (e.g., MYC, MYCL, and/or MYCN).
  • the compound, pharmaceutical composition, kit, use, or method modulates (e.g., inhibits) somatic amplification of Myc (e.g., MYC, MYCL, and/or MYCN).
  • the compound, pharmaceutical composition, kit, use, or method regulates (e.g., down-regulates) the transcription of genes controlled by Myc (e.g., MYC, MYCL, and/or MYCN).
  • Myc e.g., MYC, MYCL, and/or MYCN
  • the compound, pharmaceutical composition, kit, use, or method modulates (e.g., inhibits) the transcription of genes controlled by Myc (e.g., c-Myc, L-Myc, or N-Myc) in
  • the compound, pharmaceutical composition, kit, use, or method modulates (e.g., decreases) the stability of a protein that encodes Myc (e.g., MYC, MYCL, and/or MYCN).
  • the compound, pharmaceutical composition, kit, use, or method modulates (e.g., decreases) the stability of Myc.
  • the compounds or pharmaceutical compositions described herein selectively inhibit the activity of cells expressing Myc, compared to the inhibition of the activity of cells not expressing Myc.
  • the selectivity is at least 2-fold, at least 3-fold, at least 5-fold, or at least 10-fold.
  • the selectivity is not more than 10-fold, not more than 5-fold, not more than 3-fold, or not more than 2-fold. Combinations of the above-referenced ranges (e.g., at least 2-fold and not more than 10-fold) are also within the scope of the disclosure.
  • Another aspect of the present disclosure relates to methods of treating a disease (e.g., a disease associated with Myc (e.g., a disease associated with aberrant activity (e.g., increased activity) of Myc) in a subject in need thereof), the methods comprising administering to the subject an effective amount (e.g., therapeutically effective amount) of a compound or pharmaceutical composition described herein.
  • a disease e.g., a disease associated with Myc (e.g., a disease associated with aberrant activity (e.g., increased activity) of Myc) in a subject in need thereof
  • an effective amount e.g., therapeutically effective amount
  • a disease described herein is associated with Myc. In certain embodiments, a disease described herein is associated with aberrant activity (e.g., increased or decreased activity) of Myc. In certain embodiments, a disease described herein is associated with increased activity of Myc. In certain embodiments, a disease described herein is associated with the increased stability of Myc (e.g., MYC, MYCL, and/or MYCN). In certain embodiments, a disease described herein is associated with increased stability of Myc. In certain embodiments, a disease being treated is a proliferative disease. In certain embodiments, the disease is cancer.
  • the cancer is lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung).
  • the cancer is brain cancer (e.g., meningioma, glioblastomas, glioma (e.g., astrocytoma, oligodendroglioma), medulloblastoma).
  • a disease described herein is lymphoma (e.g., Hodgkin lymphoma, non-Hodgkin lymphoma (e.g., Burkitt's lymphoma)).
  • a disease described herein is a benign neoplasm.
  • the disease is associated with pathological angiogenesis.
  • the present disclosure provides the pharmaceutical compositions described herein for use in binding MAX, modulating (e.g., inhibiting) the activity of Myc, Mad, or Mxi1, treating a disease associated with Myc (e.g., disease associated with aberrant activity (e.g., increased activity) of Myc), treating and/or preventing a disease (e.g., proliferative disease), preventing a disease associated with Myc (e.g., disease associated with aberrant activity (e.g., increased activity) of Myc).
  • a disease associated with Myc e.g., disease associated with aberrant activity (e.g., increased activity) of Myc
  • a disease associated with Myc e.g., proliferative disease
  • a disease associated with Myc e.g., disease associated with aberrant activity (e.g., increased activity) of Myc.
  • the compounds provided herein can be prepared from readily available starting materials using methods known in the art, such as the methods described in Shaw et al., Angew. Chem. Int. Ed., 2006, 45, 1722-1726. Where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by those skilled in the art by routine experimentation.
  • FIGS. 5A to 5B An overview of an exemplary synthesis of compound KI-MS2-008 (compound 8) is shown in FIGS. 5A to 5B .
  • SMM small-molecule microarray
  • DOS Broad Institute's diversity-oriented synthesis
  • NPC natural product and commercial
  • Z-scores were computed for each compound according to published methods [8]. Analysis of the composite Z-scores corresponding to the SMM screen revealed several assay positives.
  • IC 50 IC 50 IC 50 ( ⁇ M) ( ⁇ M) ( ⁇ M) Com- Reporter Myc Myc pound R 1 R 2 R 3 R 4 assay ON OFF 1a H H H H >50 2a H H H 16.76 >50 >50 3a H H 6.19 11.44 >50 4a H H 7.67 31.78 >50 5a H H 4.81 19.34 >50 6a H H 17.20 >50 >50 7a H H 3.38 39.27 >50 8a H H >50 >50 >50 >50 9a H H 10a H H 2.15 11a H H 10.14 12a H H 18.73 13a H Cl 5.94 25.80 >50 14a H H 9.34 15 a H 11.70 14.50 >50 15 b H 4.74 8.49 >50 15 c H 4.77 16.58 >50 16a H 7.88 17a H 4.7 a Racemic mixture.
  • the effect of Compound 1 on cell viability in several cancer cell lines and normal human astrocytes (NHA) was determined.
  • the cancer cell lines employed in the assay included those corresponding to Burkitt's lymphoma (ST486 and CA46), small cell lung cancer (NCI-H1963), and glioblastoma (GBM4).
  • the cell viability of normal human astrocytes (NHA) was also assayed. Exemplary results are shown in FIG. 2 , where viability was assessed by CELL TITER GLO assay (Promega).
  • Compound 1 demonstrated an effect in cell viability in a variety of cancer cell lines, consistent with the notion that Myc is a key oncoprotein in a broad range of cancers.
  • the effects of other compounds described herein on cell viability in several cancer cell lines were also determined, and exemplary results are shown in Table 2, where viability was assessed by CELL TITER GLO assay (Promega).
  • FIGS. 3A to 3B Exemplary results are shown in FIGS. 3A to 3B , where cell viability was assessed by CELL TITER GLO assay (Promega).
  • FIG. 3A depicts the assay results for cells expressing Myc
  • FIG. 3B depicts the assay results for non-Myc expressing cells.
  • Compound 1 demonstrated a selectivity for cells expressing Myc and exhibited decreased cell viability, compared to non-Myc expressing cells in cancer cell lines.
  • the selectivity of other compounds described herein in cancer cell line cancer cell line P493-6 was also determined, and exemplary results are shown in Table 2, where viability was assessed by CELL TITER GLO assay (Promega).
  • Compound 1 was modified to include a biotinylated probe, which had been shown to be tolerated during an evaluation of select compounds (Table 2).
  • Compound 5 contains a biotinylated probe, and was found to have an IC 50 value of 5.4 ⁇ M in Myc reporter assay.
  • the structure of Compound 5 allowed for linking Compound 1 to beads (streptavidin agarose, Pierce, Thermo Fisher after Scientific).
  • beads were washed three times with 500 ⁇ L DMSO, followed by three washes with 500 ⁇ L wash buffer (150 mM NaCl, 50 mM Tris, protease inhibitor cocktail, phosphatase inhibitors, pH 7.5).
  • 500 ⁇ L wash buffer 150 mM NaCl, 50 mM Tris, protease inhibitor cocktail, phosphatase inhibitors, pH 7.5.
  • Frozen samples were brought to room temperature (RT) then reconstituted in 20 ⁇ l methanol and 80 ⁇ l water.
  • Samples were aliquoted into LCMS tubes with preslit caps and were run on C18 column with 5% ACN in water+0.1% FA as mobile phase A and 95% ACN in water+0.1% as mobile phase B.
  • a linear gradient was used: 0-0.5 min 0% B; 0.5-10.5 min 0-100% B; 10.5-15.5 min 100% B; 15.5-17.5 min 100-0% B; run stopped at 23 min.
  • Flow rate was 0.4 ml/min and injection volume was 10 ⁇ l.
  • the mass spec (Sciex API4000) was operated under multiple reaction monitoring mode scanning for the 4 most prominent fragments of the compound: m/z 105.1, 519.1, 416, 205.1 (blue, red, green, and grey, respectively).
  • the parameters were: curtain gas 25 units; ion source gas 1, 30 units; ion source gas 2, 30 units; temperature 550° C.; ion spray voltage 5500 V; declustering potential 96 V, and collision energy 57 eV.
  • the results are shown in FIG. 21 and demonstrate that LC/MS methods for compound detection were found and developed.
  • Samples of 10 ⁇ l plasma were extracted in eppendorf tubes by quickly adding 500 ⁇ l of cold MeOH, followed by 300 ⁇ l cold water, and 500 ⁇ l cold chloroform.
  • the tubes were mixed by hand for a few seconds, vortexed at max speed for 10 min at 4° C., and then centrifuged for 5 min at max speed at 4° C.
  • the chloroform layer bottom layer was transferred to a new tube and evaporated in a SpeedVac.
  • the tubes were frozen at ⁇ 80° C. until LCMS analysis.
  • Example 7 MS2-008 is Detectable in Processed Plasma
  • a plasma protein binding study was conducted to determine if the MS2-008 compound has high or low protein extraction using the above plasma extraction method.
  • Plasma was processed from blood samples. Water and plasma samples were spiked with MS2-008 and subjected to the plasma extraction protocol. Preliminary results showed minimal differences between extraction from water or plasma.
  • a serial dilution-lowest detection limit test was also conducted.
  • the results, as shown in FIG. 23 indicate a demonstrable level of compound with IV and no significant change in oral saline or cyclodextrin as compared to control plasma.
  • n 3 animals for each group; paired t-test between control plasma and other sample sets: *p ⁇ 0.001 (see FIG. 23 ).
  • Drug clearance is rapid for the first couple of hours between 30 min and 1 hour the concentration drops 50% and between 1-2 hours it drops another 50%. The compound concentration then remains relatively stable between 2 and 6 hours and drops back to non-detectable by 24 hours.
  • Histology results showed that following an examination of sections of liver and kidney from all study animals, no signs of hepatic or renal organ damage were observed.
  • mice weights did not change and histology results for all treated mice indicate that there was no signs of organ toxicity at the doses used ( ⁇ 5 ⁇ and 10 ⁇ concentrations used in earlier efficacy studies).
  • Plasma samples collected at the time of study termination indicate that following repeated dosing, the compound is almost completely cleared within 24 hours. However there is a slightly higher level of the compound remaining in the plasma in the higher dose at the conclusion of the study (see FIG. 26A ).
  • the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim.
  • any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim.
  • elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements and/or features, certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements and/or features.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
US15/435,003 2016-02-16 2017-02-16 Max binders as MYC modulators and uses thereof Active US10106555B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US15/435,003 US10106555B2 (en) 2016-02-16 2017-02-16 Max binders as MYC modulators and uses thereof
US16/167,238 US10865213B2 (en) 2016-02-16 2018-10-22 Max binders as MYC modulators and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662295996P 2016-02-16 2016-02-16
US15/435,003 US10106555B2 (en) 2016-02-16 2017-02-16 Max binders as MYC modulators and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/167,238 Division US10865213B2 (en) 2016-02-16 2018-10-22 Max binders as MYC modulators and uses thereof

Publications (2)

Publication Number Publication Date
US20170233405A1 US20170233405A1 (en) 2017-08-17
US10106555B2 true US10106555B2 (en) 2018-10-23

Family

ID=58191662

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/435,003 Active US10106555B2 (en) 2016-02-16 2017-02-16 Max binders as MYC modulators and uses thereof
US16/167,238 Active US10865213B2 (en) 2016-02-16 2018-10-22 Max binders as MYC modulators and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/167,238 Active US10865213B2 (en) 2016-02-16 2018-10-22 Max binders as MYC modulators and uses thereof

Country Status (11)

Country Link
US (2) US10106555B2 (pt)
EP (1) EP3416950A1 (pt)
JP (1) JP2019505548A (pt)
KR (1) KR20180107261A (pt)
CN (1) CN109071456A (pt)
AU (1) AU2017221422A1 (pt)
BR (1) BR112018016133A2 (pt)
CA (1) CA3012846A1 (pt)
MX (1) MX2018009913A (pt)
RU (1) RU2018132559A (pt)
WO (1) WO2017143059A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10865213B2 (en) 2016-02-16 2020-12-15 Massachusetts Institute Of Technology Max binders as MYC modulators and uses thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11613535B2 (en) * 2018-07-09 2023-03-28 The Scripps Research Institute Compounds for MYC inhibition
CN111274691A (zh) * 2020-01-16 2020-06-12 西安交通大学 一种分析预测max相材料可形成能力的方法
CN115485272A (zh) 2020-03-27 2022-12-16 朗多生物制药股份有限公司 Plxdc2配体
CA3208313A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
CN116908444B (zh) * 2023-09-13 2023-12-19 中国医学科学院北京协和医院 血浆max自身抗体在晚期非小细胞肺癌pd-1单抗联合化疗治疗预后预测中的应用

Citations (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02191695A (ja) 1989-01-20 1990-07-27 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02196887A (ja) 1989-01-26 1990-08-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02208392A (ja) 1989-02-08 1990-08-17 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02222488A (ja) 1989-02-23 1990-09-05 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227489A (ja) 1989-02-28 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227491A (ja) 1989-03-01 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227490A (ja) 1989-02-28 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02242882A (ja) 1989-03-16 1990-09-27 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02247282A (ja) 1989-03-22 1990-10-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02247280A (ja) 1989-03-20 1990-10-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02255793A (ja) 1989-03-30 1990-10-16 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02255794A (ja) 1989-03-29 1990-10-16 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH08231541A (ja) 1995-03-01 1996-09-10 Nippon Soda Co Ltd イミダゾリン誘導体および除草剤
US5965574A (en) 1996-08-13 1999-10-12 Chen; Yuhpyng Liang Heteroaryl amines as novel acetylcholinesterase inhibitors
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
JP2003057783A (ja) 2001-08-21 2003-02-26 Konica Corp 銀色調を改良した光熱写真画像形成材料
JP2003075957A (ja) 2001-09-07 2003-03-12 Konica Corp スケイル模様のない光熱写真画像形成材料
JP2003075955A (ja) 2001-09-03 2003-03-12 Konica Corp 銀色調を改良した光熱写真画像形成材料
JP2004131463A (ja) 2002-08-14 2004-04-30 Mitsubishi Chemicals Corp 有機金属錯体、発光色素、有機電界発光素子材料および有機電界発光素子
WO2004080989A1 (ja) 2003-03-10 2004-09-23 Sumitomo Chemical Company Limited フラン化合物の製造方法
WO2005002503A2 (en) 2003-05-13 2005-01-13 Icagen, Inc. Asymmetric benzimidazoles and related compounds as potassium channel modulators
WO2005026112A2 (en) 2003-09-12 2005-03-24 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
WO2005033090A1 (ja) 2003-10-06 2005-04-14 Sumitomo Chemical Company, Limited 芳香族化合物
WO2006031894A2 (en) 2004-09-13 2006-03-23 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
JP2006084592A (ja) 2004-09-14 2006-03-30 Fuji Photo Film Co Ltd 感光性組成物
EP1746097A1 (en) 2005-07-20 2007-01-24 Aventis Pharma S.A. 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
WO2007047604A2 (en) 2005-10-18 2007-04-26 Elixir Pharmaceuticals, Inc. Sirt1 inhibition
JP2007217298A (ja) 2006-02-14 2007-08-30 Daicel Chem Ind Ltd アミノ基含有アダマンタン誘導体とその製造方法
WO2007146712A2 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
WO2008012010A1 (en) 2006-07-27 2008-01-31 Ucb Pharma, S.A. Fused oxazoles & thiazoles as histamine h3- receptor ligands
WO2009092764A1 (en) 2008-01-24 2009-07-30 Ucb Pharma, S.A. Compounds comprising a cyclobutoxy group
WO2009108905A2 (en) 2008-02-28 2009-09-03 Life Technologies Corporation Fluorescence polarization herg assay
WO2010054398A1 (en) 2008-11-10 2010-05-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2010075282A1 (en) 2008-12-22 2010-07-01 University Of Washington Molecular inhibitors of the wnt/beta-catenin pathway
JP2010207767A (ja) 2009-03-12 2010-09-24 Japan Science & Technology Agency 光学活性アルコール化合物の製法
US20110152240A1 (en) 2009-12-04 2011-06-23 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
WO2012153780A1 (ja) 2011-05-11 2012-11-15 出光興産株式会社 新規化合物、有機エレクトロルミネッセンス素子用材料及び有機エレクトロルミネッセンス素子
WO2013038650A1 (ja) 2011-09-13 2013-03-21 出光興産株式会社 縮合複素芳香族誘導体、有機エレクトロルミネッセンス素子用材料及びそれを用いた有機エレクトロルミネッセンス素子
US20130184240A1 (en) 2010-09-10 2013-07-18 Shionogi & Co., Ltd. Hetero ring-fused imidazole derivative having ampk activating effect
WO2013177241A1 (en) 2012-05-22 2013-11-28 Trustees Of Dartmouth College Method for synthesizing cycloalkanyl(b}indoles, cycloalkanyl(b) benzofurans, cycloalkanyl(b)benzothiophenes, compounds and methods of use
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2014132971A1 (ja) 2013-02-28 2014-09-04 住友化学株式会社 縮合複素環化合物及びその有害生物防除用途
US20140296307A1 (en) 2013-03-27 2014-10-02 University Of Maryland, Baltimore Potent analogues of the c-myc inhibitor 10074-g5 with improved cell permeability
WO2015089180A1 (en) 2013-12-11 2015-06-18 The Scripps Research Institute Small molecule c-myc inhibitors
US20160168165A1 (en) 2014-12-10 2016-06-16 Massachusetts Institute Of Technology Myc modulators and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02194085A (ja) 1989-01-24 1990-07-31 Dainippon Ink & Chem Inc 強誘電性液晶組成物
AU6331099A (en) 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders
ATE548031T1 (de) 2000-12-18 2012-03-15 Inst Med Molecular Design Inc Inhibitoren gegen die produktion und freisetzung entzündungfördernder zytokine
CA2460541A1 (en) 2001-09-14 2003-04-03 Helle Birk Olsen Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer
US20050042674A9 (en) 2002-02-21 2005-02-24 Lin Yu Common ligand mimics: thiazolidinediones and rhodanines
GB2387172A (en) 2002-03-28 2003-10-08 Pantherix Ltd [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials
WO2004024061A2 (en) 2002-04-30 2004-03-25 Merck & Co., Inc. Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
JP2008505866A (ja) 2004-07-09 2008-02-28 ノボ　ノルディスク　アクティーゼルスカブ インスリンを含有する薬学的製剤
US8865909B2 (en) 2008-11-20 2014-10-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-biofilm agents
WO2011063502A1 (en) 2009-11-24 2011-06-03 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
TWI618706B (zh) * 2012-12-07 2018-03-21 維泰克斯製藥公司 用作ａｔｒ激酶抑制劑之化合物
US8901164B2 (en) * 2013-03-07 2014-12-02 University Of Maryland, Baltimore Amphipathic and other double-sided alpha-helix mimetics based on a 1,2-diphenylacetylene scaffold
BR112015022417A2 (pt) 2013-03-14 2017-07-18 Convergene Llc métodos e composições para inibição de proteínas contendo bromodomínio
BR112018016133A2 (pt) 2016-02-16 2019-01-02 Massachusetts Inst Technology aglutinantes de max como moduladores de myc e usos dos mesmos

Patent Citations (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02191695A (ja) 1989-01-20 1990-07-27 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02196887A (ja) 1989-01-26 1990-08-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02208392A (ja) 1989-02-08 1990-08-17 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02222488A (ja) 1989-02-23 1990-09-05 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227489A (ja) 1989-02-28 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227490A (ja) 1989-02-28 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227491A (ja) 1989-03-01 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02242882A (ja) 1989-03-16 1990-09-27 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02247280A (ja) 1989-03-20 1990-10-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02247282A (ja) 1989-03-22 1990-10-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02255794A (ja) 1989-03-29 1990-10-16 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02255793A (ja) 1989-03-30 1990-10-16 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH08231541A (ja) 1995-03-01 1996-09-10 Nippon Soda Co Ltd イミダゾリン誘導体および除草剤
US5965574A (en) 1996-08-13 1999-10-12 Chen; Yuhpyng Liang Heteroaryl amines as novel acetylcholinesterase inhibitors
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
JP2003057783A (ja) 2001-08-21 2003-02-26 Konica Corp 銀色調を改良した光熱写真画像形成材料
JP2003075955A (ja) 2001-09-03 2003-03-12 Konica Corp 銀色調を改良した光熱写真画像形成材料
JP2003075957A (ja) 2001-09-07 2003-03-12 Konica Corp スケイル模様のない光熱写真画像形成材料
JP2004131463A (ja) 2002-08-14 2004-04-30 Mitsubishi Chemicals Corp 有機金属錯体、発光色素、有機電界発光素子材料および有機電界発光素子
WO2004080989A1 (ja) 2003-03-10 2004-09-23 Sumitomo Chemical Company Limited フラン化合物の製造方法
WO2005002503A2 (en) 2003-05-13 2005-01-13 Icagen, Inc. Asymmetric benzimidazoles and related compounds as potassium channel modulators
WO2005026112A2 (en) 2003-09-12 2005-03-24 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
WO2005033090A1 (ja) 2003-10-06 2005-04-14 Sumitomo Chemical Company, Limited 芳香族化合物
WO2006031894A2 (en) 2004-09-13 2006-03-23 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
JP2006084592A (ja) 2004-09-14 2006-03-30 Fuji Photo Film Co Ltd 感光性組成物
EP1746097A1 (en) 2005-07-20 2007-01-24 Aventis Pharma S.A. 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
WO2007047604A2 (en) 2005-10-18 2007-04-26 Elixir Pharmaceuticals, Inc. Sirt1 inhibition
JP2007217298A (ja) 2006-02-14 2007-08-30 Daicel Chem Ind Ltd アミノ基含有アダマンタン誘導体とその製造方法
WO2007146712A2 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
WO2008012010A1 (en) 2006-07-27 2008-01-31 Ucb Pharma, S.A. Fused oxazoles & thiazoles as histamine h3- receptor ligands
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009092764A1 (en) 2008-01-24 2009-07-30 Ucb Pharma, S.A. Compounds comprising a cyclobutoxy group
WO2009108905A2 (en) 2008-02-28 2009-09-03 Life Technologies Corporation Fluorescence polarization herg assay
WO2010054398A1 (en) 2008-11-10 2010-05-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2010075282A1 (en) 2008-12-22 2010-07-01 University Of Washington Molecular inhibitors of the wnt/beta-catenin pathway
JP2010207767A (ja) 2009-03-12 2010-09-24 Japan Science & Technology Agency 光学活性アルコール化合物の製法
US20110152240A1 (en) 2009-12-04 2011-06-23 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
US20130184240A1 (en) 2010-09-10 2013-07-18 Shionogi & Co., Ltd. Hetero ring-fused imidazole derivative having ampk activating effect
WO2012153780A1 (ja) 2011-05-11 2012-11-15 出光興産株式会社 新規化合物、有機エレクトロルミネッセンス素子用材料及び有機エレクトロルミネッセンス素子
WO2013038650A1 (ja) 2011-09-13 2013-03-21 出光興産株式会社 縮合複素芳香族誘導体、有機エレクトロルミネッセンス素子用材料及びそれを用いた有機エレクトロルミネッセンス素子
WO2013177241A1 (en) 2012-05-22 2013-11-28 Trustees Of Dartmouth College Method for synthesizing cycloalkanyl(b}indoles, cycloalkanyl(b) benzofurans, cycloalkanyl(b)benzothiophenes, compounds and methods of use
WO2014132971A1 (ja) 2013-02-28 2014-09-04 住友化学株式会社 縮合複素環化合物及びその有害生物防除用途
US20140296307A1 (en) 2013-03-27 2014-10-02 University Of Maryland, Baltimore Potent analogues of the c-myc inhibitor 10074-g5 with improved cell permeability
WO2015089180A1 (en) 2013-12-11 2015-06-18 The Scripps Research Institute Small molecule c-myc inhibitors
US20160168165A1 (en) 2014-12-10 2016-06-16 Massachusetts Institute Of Technology Myc modulators and uses thereof

Non-Patent Citations (36)

* Cited by examiner, † Cited by third party
Title
Boxer et al., Translocations involving c-myc and c-myc function. Oncogene. Sep. 10, 2001;20(40):5595-610.
CAS Registry No. 1024883-05-3, STN Entry Date Jun. 3, 2008.
CAS Registry No. 1458427-65-0, STN Entry Date Oct. 15, 2013.
CAS Registry No. 439814-35-4, STN Entry Date Jul. 23, 2002.
CAS Registry No. 444653-79-6, STN Entry Date Aug. 22, 2002.
CAS Registry No. 444693-02-1, STN Entry Date Aug. 22, 2002.
CAS Registry No. 444714-90-3, STN Entry Date Aug. 22, 2002.
CAS Registry No. 497836-62-1, STN Entry Date Mar. 11, 2003.
CAS Registry No. 641607-16-1, STN Entry Date Jan. 26, 2004.
CAS Registry No. 675830-23-6, STN Entry Date Apr. 16, 2004.
CAS Registry No. 83490-12-4, STN Entry Date Nov. 16, 1984.
CAS Registry No. 920536-51-2, STN Entry Date Feb. 12, 2007.
Dang et al., c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. Jan. 1999;19(1):1-11.
Dang et al., The c-Myc target gene network.Semin Cancer Biol. Aug. 2006;16(4):253-64. Epub Jul. 25, 2006.
Duffner et al., A pipeline for ligand discovery using small-molecule microarrays. Curr Opin Chem Biol. Feb. 2007;11(1):74-82. Epub Dec. 13, 2006.
Eilers et al., Myc's broad reach. Genes Dev. Oct. 15, 2008;22(20):2755-66. doi: 10.1101/gad.1712408.
Felsher et al., Reversible tumorigenesis by MYC in hematopoietic lineages.Mol Cell. Aug. 1999;4(2):199-207.
Frost et al., Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol. Mar. 2004;121(3):384-92.
Frye et al., The art of the chemical probe. Nat Chem Biol. Mar. 2010;6(3):159-161.
Huang et al., Photocycloadditions of substituted oxazoles with isoquinoline-1,3,4-trione-chemo, regio-, diastereoselectivities and transformation of the photocycloadducts. Org Biomol Chem. Aug 14, 2013;11(30):5023-33. doi: 10.1039/c3ob40645h. Epub Jun. 26, 2013.
Huang et al., Photocycloadditions of substituted oxazoles with isoquinoline-1,3,4-trione—chemo, regio-, diastereoselectivities and transformation of the photocycloadducts. Org Biomol Chem. Aug 14, 2013;11(30):5023-33. doi: 10.1039/c3ob40645h. Epub Jun. 26, 2013.
International Preliminary Report on Patentability for PCT/US2015/065044, dated Jun. 22, 2017.
International Search Report and Written Opinion for PCT/US2015/065044, dated Feb. 22, 2016.
International Search Report and Written Opinion for PCT/US2017/018162, dated Apr. 20, 2017.
Leskov et al., Rapid generation of human B-cell lymphomas via combined expression of Myc and Bc12 and their use as a preclinical model for biological therapies. Oncogene. Feb. 21, 2013;32(8):1066-72. doi: 10.1038/onc.2012.117. Epub Apr. 9, 2012.
Mitchell et al., A structurally diverse library of polycyclic lactams resulting from systematic placement of proximal functional groups. Angew Chem Int Ed Engl. Mar. 3, 2006;45(11):1722-6.
Nitsche et al., Thiazolidinone-peptide hybrids as dengue virus protease inhibitors with antiviral activity in cell culture. J Med Chem. Nov. 14, 2013;56(21):8389-403. doi: 10.1021/jm400828u.
Norgren et al., On-Resin Click-Glycoconjugation of Peptoids. Synthesis. 2009; 3: 488-94.
Pajic et al., Cell cycle activation by c-myc in a burkitt lymphoma model cell line. Int J Cancer. Sep. 15, 2000;87(6):787-93.
Seiler et al., ChemBank: a small-molecule screening and cheminformatics resource database. Nucleic Acids Res. Jan. 2008;36(Database issue):D351-9. Epub Oct. 18, 2007.
Sekar et al., S-arylation of mercaptobenzimidazoles using Cu(I) catalysts-experimental and theoretical observations. Tetrahedron Letters. 2011;52:3347-52.
Soucek et al., Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. Mar. 1, 2013;27(5):504-13. doi: 10.1101/gad.205542.112.
Vanriggelen et al., MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. Apr. 2010;10(4):301-9. doi: 10.1038/nrc2819.
Verma et al., Design and Synthesis of Benzimidazole-Linked meta-Substituted Benzylidenes/Benzyls as Biologically Significant New Chemical Entities. Synthetic Communications 2013; 43(14):1882-95.
Vita et al., The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol. Aug. 2006;16(4):318-30. Epub Aug. 3, 2006.
Wang et al., Small-molecule reagents for cellular pull-down experiments. Bioconjug Chem. Mar. 2008;19(3):585-7. doi: 10.1021/bc700297j. Epub Jan. 15, 2008.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10865213B2 (en) 2016-02-16 2020-12-15 Massachusetts Institute Of Technology Max binders as MYC modulators and uses thereof

Also Published As

Publication number Publication date
MX2018009913A (es) 2018-11-29
US10865213B2 (en) 2020-12-15
WO2017143059A1 (en) 2017-08-24
JP2019505548A (ja) 2019-02-28
US20190144466A1 (en) 2019-05-16
BR112018016133A2 (pt) 2019-01-02
RU2018132559A (ru) 2020-03-17
AU2017221422A1 (en) 2018-08-16
KR20180107261A (ko) 2018-10-01
CA3012846A1 (en) 2017-08-24
EP3416950A1 (en) 2018-12-26
CN109071456A (zh) 2018-12-21
US20170233405A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
US10975055B2 (en) Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
US11932625B2 (en) Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
US10017520B2 (en) Myc modulators and uses thereof
US10865213B2 (en) Max binders as MYC modulators and uses thereof
US20220227734A1 (en) Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof
US10711036B2 (en) MALT1 inhibitors and uses thereof
US11634450B2 (en) DOT1L degraders and uses thereof
US20230148448A9 (en) Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US20220372017A1 (en) Hck degraders and uses thereof
US20220395509A1 (en) A pyrazolopyrimidine derivative as a hck inhibitor for use in therapy, in particular myd88 mutated diseases
US20180237407A1 (en) Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
US20220242872A1 (en) E3 ligase binders and uses thereof
US20220048942A1 (en) Dot1l degraders and uses thereof
US11014876B2 (en) Polyamine sulfonamides and uses thereof
US20230382865A1 (en) Histone demethylase 5 inhibitors and uses thereof
US20230339865A1 (en) Quinazoline-derived hck inhibitors for use in the treatment of myd88 mutated diseases

Legal Events

Date Code Title Description
AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:MASSACHUSETTS INSTITUTE OF TECHNOLOGY;REEL/FRAME:042086/0689

Effective date: 20170320

AS Assignment

Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MASSACHUSET

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOEHLER, ANGELA N.;EVANS, HELEN L.;STRUNTZ, NICHOLAS B.;AND OTHERS;SIGNING DATES FROM 20170404 TO 20170621;REEL/FRAME:043360/0866

AS Assignment

Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MASSACHUSET

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOEHLER, ANGELA N.;STEFAN, ERIC;CABALLERO, FRANCISCO;AND OTHERS;SIGNING DATES FROM 20170404 TO 20170621;REEL/FRAME:043493/0252

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4